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RESUMÉ EN FRANÇAIS 
 
La consommation abusive de certaines substances a toujours existé au sein de 
nombreuses civilisations et ceci à travers les âges. Si l‟usage de l‟opium constitue le plus vieil 
exemple reconnu d‟abus de drogue, de nombreux composés plus récents présentant des 
propriétés addictives ont vu le jour, faisant de plus en plus d‟adeptes. De façon surprenante, 
parmi tous ces consommateurs, seule une fraction (< 20 %) présente une susceptibilité à 
l‟addiction. En effet, ces personnes dites „accros‟ vont consommer compulsivement des 
drogues en dépit des conséquences qui peuvent être néfastes pour leur santé, leur vie sociale 
et professionnelle. Les origines de l‟addiction restent néanmoins complexes à établir mais la 
génétique et les modifications engendrées dans le cerveau par la prise de drogue semblent 
impliquées. Ainsi, une seule exposition à la drogue est suffisante pour induire des 
changements dans le cerveau et ces derniers sont tenus responsables de l‟apparition de 
comportements addictifs chez les personnes génétiquement prédisposées. 
Toutes les drogues dites addictives ont pour cible le système mésolimbique 
dopaminergique et plus particulièrement l‟aire tegmentale ventrale (ATV), provoquant une 
augmentation de la libération de dopamine. Tout au long de ce projet de thèse, nous avons 
focalisé notre attention sur les effets de l‟acide -hydroxybutyrique (GHB), une drogue 
addictive de plus en plus populaire. Le GHB est en effet abusivement consommé à travers le 
monde depuis une vingtaine d‟années mais les mécanismes cellulaires et moléculaires qui 
expliquent ses propriétés récompensantes demeurent inconnus à ce jour. Pourtant, le récepteur 
permettant de véhiculer les effets addictifs du GHB à été identifié : il s‟agit du récepteur 
GABAB. Lorsque celui-ci est génétiquement supprimé (souris GABABR1 knock-out), les 
effets du GHB sont totalement absents. Il a été démontré que l‟activation de ce récepteur était 
suivie de celle de protéines Gi/o, ces dernières interagissant avec des effecteurs identifiés 
comme étant les canaux potassiques GIRK. 
Afin de mieux cerner les mécanismes d‟action du GHB, nous avons étudié les 
courants GIRK évoqués par l‟activation du GABABR et ceci dans les deux principaux types 
neuronaux de l‟ATV. De façon intéressante, le couplage existant entre le récepteur et ses 
effecteurs est plus faible dans les neurones DA que dans les neurones GABA. Nous avons 
ensuite démontré qu‟une composition et un assemblage spécifique en sous-unités GIRK 
étaient responsables de ce faible couplage au sein des cellules DA et ceci indépendamment du 
- 2 - 
 
type de récepteur couplé aux protéines G (RCPG) impliqué. Cette différence de couplage a 
une conséquence directe au plan fonctionnel puisque le GHB a un effet bidirectionnel sur 
l‟activité cellulaire des neurones DA de l‟ATV. Finalement, nous avons trouvé que 
l‟administration chronique de drogue, telles que le GHB ou la morphine, augmentait le 
couplage GABABR-canaux GIRK, ce qui fait perdre au GHB ses effets récompensants. 
Ensemble, ces résultats mettent en lumière un mécanisme particulier de tolérance au GHB et 
apportent de nouvelles idées quant à la manière de bloquer les effets de certaines drogues en 
modulant le couplage RCPG-canaux GIRK. 
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SUMMARY 
 
Historically, many substances have been abused all over the world across numerous 
civilizations. If opium consumption consists probably the oldest example of abuse, more 
recently, a lot of new compounds with addictive properties appeared, recruiting more and 
more users. Surprisingly, among these drugs consumers, only a fraction (< 20 %) is 
susceptible to addiction. These „addicts‟ exhibit a compulsive drug use despite negative 
consequences, causing serious troubles for their health or their social life. The origins of 
addiction are complex to define but their roots probably take place in genetics and in the 
brain‟s modifications occurring after drug of abuse exposition. Thus, a single drug 
administration is sufficient to induce modifications in the brain and such changes are thought 
to be responsible for addictive behaviours in people genetically predisposed. 
All the drugs of abuse target the same neuronal network, the mesolimbic dopamine 
system that originates in the ventral tegmental area (VTA), inducing a common increase of 
dopamine release. During this thesis project, we focused our attention on the γ-
hydroxybutyrate (GHB) effects, an increasing popularity drug of abuse. GHB is abused all 
over the world for twenty years but the cellular and molecular mechanisms underlying its 
addictive properties are still unknown. However, the GABABR is known to be responsible for 
the mediation of the GHB rewarding effects since in GABABR1
–/–
 mice these later are totally 
absent. The activation of this receptor triggers a Gi/o-protein signaling that allow an 
interactions with its effectors: the GIRK channels. 
In order to understand how GHB mediates its rewarding effects, we looked at the 
GIRK currents elicited by the GABABR activation in the two main neuronal populations of 
the VTA. Interestingly, the coupling efficiency existing between the receptor and its effectors 
was weaker in the DA neurons than in GABA cells. We then demonstrated that a specific 
GIRK subunit composition and assembly was responsible for such low coupling in DA cells, 
independently to the type of GPCR implicated. As a functional consequence, GHB exerts a 
bidirectional effect on the DA neurons cellular activity. Finally, we found that chronic drug 
administration, as with GHB or morphine, increased the GABABR-GIRK channel coupling 
efficiency and provoked the loss of GHB rewarding effects. Altogether, these results highlight 
a specific mechanism of tolerance to GHB and bring new ideas on the GPCR-GIRK channel 
coupling modulation in order to block the effects of certain addictive drugs. 
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1. INTRODUCTION 
 
Many substances have been abused for millenaries by human beings across multitude 
of civilizations. A large majority of these substances are found in the vegetal world, regarding 
the active compounds extracted from plants. Historically, the oldest example of substance of 
abuse consumption consists in the discovery of opium traces in european neolithic houses 
aged from 5000 years A.D. Opium plants (Papaver somniferum), from where morphine and 
heroin were later derived, have also been largely used by pharaohs in old Egypt or by the 
society of anthic Greece. More recently, many synthetic compounds appeared, forming new 
families of drugs of abuse. Human‟s history and drugs of abuse‟s history are closely linked in 
several levels, notably Culture, Philosophy, Mysticism, Religion, Science and Medicine. 
Nevertheless, episodes of abuse substances do not reflect a strict human behaviour. We will 
see that animals in their natural environment can present exacerbated consumption of 
addictive substances and that animal models of abuse have been reproduced in laboratory. 
Moreover, humans and animals, that are genetically related, exhibit similar behaviours 
leading, in certain circumstances, to addiction. 
Despite the huge diversity of drugs of abuse, the research deploys its efforts to find 
appropriate and innovative treatments to cure addiction. However, the fast renewal of 
addictive drugs doesn‟t facilitate these tasks. For example, since the 90‟s, a new chemical 
compound presenting addictive properties has been abused all over the world: the -
hydroxybutyrate (GHB). In the present report, we expose the approaches we developed to 
study and define the mechanisms by which this substance acts on the brain, bringing new 
insights in addiction comprehension. 
 
1.1.  Concept of addiction 
1.1.1. Definition of addiction 
 
Addiction is defined as a “compulsive drug use despite negative consequences” 
(World Health Organization 1969). Indeed, drugs users can have recurring episodes during 
which they will seek for "their dose" even if the consequences are harmful for their health, 
their mental state or their social life. The recent notion of addiction is very often difficult to 
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perceive and most of the people have problem to discern addiction from dependence. 
Historically, dependence was associated to the physical dependence while the old term 
“psychological dependence” can be now replaced by addiction (Luscher 2007). These terms 
were revisited after the demonstration that they deal with different mechanisms acting at 
different level of the organism. 
First of all, dependence can be characterized by two main components: the tolerance 
and the withdrawal. Tolerance takes place after repetitive exposure to drugs of abuse. It refers 
to the fact that you have to increase the auto-administrated doses to maintain effects similar as 
they were previously felt. After a certain period of exposure, people are confronted to 
withdrawal syndrome when drugs of abuse are no more available. These dependence-
associated aspects only occur after repetitive drugs exposure and there are observed in 100 % 
of users. Indeed, tolerance is probably due to adaptive changes in the body, like the 
desensitization at the level of the targeted receptor that takes place after prolonged use of 
substances of abuse. In addition, after drug removal, our organism returns to its initial 
homeostatic conditions, provoking characteristic signs and symptoms during this transition 
period, where it is suddenly drugs deprived. This emerging withdrawal syndrome is variable 
from one drug to the other and among individuals. However, common aspects are persisting 
and people perceive in general the opposite symptoms of the drug's direct effects, as tiredness, 
anxiety or depression. 
Compulsive drug-seeking behaviour, relapse and craving are the main features to 
qualify addiction. In fact, after a withdrawal period, only a small fraction of people that 
previously present dependence will exhibit relapse episodes with compulsive drug-seeking 
behaviours due to craving. These addictive behaviours are closely linked to the context in 
which addictive drugs are consumed. As a consequence, a reexposure to this context is 
dangerous for people in drug rehabilitation. Among drugs consumers, the fraction of those 
susceptible to addiction, called addicts, is a bit variable considering distinct types of drugs. 
Nevertheless, since only a small proportion of the population is affected (< 20 %) one can 
assume that this specific category of persons and only this one is susceptible to addiction. 
Surprisingly, we will see in the next paragraph that „addicts‟ also exist in the animal world. 
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1.1.2.  Origins of addiction 
 
Historically, addiction has been viewed as a purely socio-cultural problem. In short, 
some people became addicts in contact of a bad environment propitious to drugs 
consumption. Since animal models of addiction were reported, this point of view was 
challenged (Deroche-Gamonet, Belin et al. 2004). Indeed, it has been possible to develop 
models of addiction where animals exhibit behaviours mimicking those of human addicts. 
Surprisingly, the percentage of cocaine addicted animals found was very similar to the 
percentage of human addicts, suggesting that the susceptibility for addiction is conserved 
through phylogeny. In this way, and even if the origins of addiction are complex to define, 
genetics is playing an important role. However, critics of these theories can still claim that 
because animals are not supposed to be confronted to substances of abuse in their natural 
environment, animal models for addiction are artificial. Nevertheless, different arguments can 
be advanced in favour of the implication of genetics in addiction. First of all, we can cite 
example of abusive consumption by wild animals, notably alcohol, in a natural environment. 
Indeed, small ancestral primates of Africa and Asia (lorises), are living in symbiosis with 
palm trees that produce a fermenting nectar rich in alcohol they largely consume (Wiens, 
under submission). Second of all, experiments have been carried out on human twins to 
estimate inheritance of addiction (Goldman, Oroszi et al. 2005). They demonstrated that the 
genetic background is primordial for drugs of abuse predisposition. So, statistics showed a 
higher risk of addiction between two persons presenting a similar genetic background, like 
monozygotic twins, in comparison with people genetically different (dizygotic twins). A good 
correlation between the heritability of addictive disorders and the relative risk of addiction 
associated to drugs of abuse was also observed. In other words, more a substance is addictive, 
more its addiction is heritable. However, we still don‟t know exactly which are the genes 
conferring vulnerability in addiction. 
In addition, interindividual variations at the genetic level cannot alone explain 
addiction. In the Literature, addiction is described as a brain‟s disease where normal learning 
and memory have been altered (Hyman 2005) or, more precisely, as “a mental disease 
affecting the brain‟s natural reward system” (Mohn, Yao et al. 2004). Despite a wide panel of 
addictive drugs that evoke a multitude of effects, they all strongly activate the reward system. 
Contrary to natural rewards, drugs exposure dramatically modifies the functionality of this 
system and lead, in certain cases, to addiction. To cite only one example, it has been shown 
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that cocaine injection in mice provokes a modification of the synaptic strength in the reward 
neuronal network (Kauer and Malenka 2007). This kind of study is very interesting because it 
shows that these changes can take place only after a single exposure to cocaine. Conscious 
that a single cocaine injection is unable to make you addicted, these brain‟s modifications 
constitute probably a gate for pathological processes induction occurring after repetitive 
exposures to addictive drugs. We will see now, in more details, what the brain‟s reward 
system is and how it is affected by such compounds. 
 
1.1.3. The reward system or mesolimbic dopamine system 
 
According to W. Schultz, rewards are objects or events that make us come back for 
more (Schultz 1998). We need them for survival and use them for behavioural choices that 
maximize them. For these two reasons, rewards can be also called positive reinforcers, 
because they increase the probability to induce a behavioural response. Rewards can be 
natural as food, love, sex, etc. but also includes shopping or monetary reward. Despite the 
large diversity of rewards tested, functional imaging experiments carried out on human brain 
confirmed the activation of a unique neuronal network: the mesolimbic dopamine (DA) 
system. Indeed, MRI revealed an activation of the same area after chocolate intake (Small, 
Zatorre et al. 2001) or after the presentation of the loved partner‟s picture (Aron, Fisher et al. 
2005). Addictive drugs can be considered as rewards due to the pleasant sensations they 
procure and because they also activate the reward system. The same patterns of activation 
were observed notably after cocaine (Breiter, Gollub et al. 1997), amphetamine (Leyton, 
Boileau et al. 2002) or ethanol exposure (Boileau, Assaad et al. 2003). 
To measure the rewarding or the reinforcing effects of a reward (natural reward or 
addictive substance), several behavioural paradigms are typically used. Conditioned place 
preference (CPP) and self-administration paradigms are the main tools generally employed 
for that purpose (Rossi 1976; Bozarth, Gerber et al. 1980). Briefly, during CPP, we measure 
the time spent in a compartment associated to a reward before and after a conditioning session 
(e.g. saline versus cocaine injection). A correlation can be done between the place preference 
for reward and the reinforcing properties of the reward tested. In addition, self-administration 
paradigm allows to actively measure the reinforcing strength of a reward. The advantages of 
this technique is to let animals press by themselves a lever to auto-administrate a substance 
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directly in the brain area we are interested in. We can have a direct estimation of the 
rewarding properties of the substance by monitoring the lever‟s presses. These pioneer 
techniques allowed researchers to identify the neuronal networks coding for reward-
associated processes. 
 
 
Figure 1 Major efferent and afferent projections of the VTA. Direct connections to and from the VTA are shown in 
black or color. Other connections are shown in gray. If known, the approximate percentage of projecting neurons 
that are cytochemically identified as dopaminergic is indicated by the color scale shown in the lower right. 
Abbreviations: LDT, laterodorsal tegmental nucleus; PPTg, pedunculopontine tegmental nucleus; LH, lateral 
hypothalamus; VP, ventral pallidum; SC, superior colliculus (from Fields, Hjelmstad et al. 2007). 
 
The reward-activated system or mesolimbic DA system was identified in 1971 and 
named in this manner because projection neurons are mainly dopaminergic (DAergic) cells. 
These projecting neurons originate in an area called the ventral tegmental area (VTA) and 
target the nucleus accumbens (NAc) and the olfactory tubercule (Ungerstedt 1971). Later 
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studies have identified others DA projection patterns, mainly to the prefrontal cortex, the 
hippocampus and the amygdala (Lindvall, Bjorklund et al. 1974; Fallon and Moore 1978; 
Swanson 1982; see Fig. 1). Among these fiber bundles, one is interesting regarding its 
implication in reward processes and its high density of DAergic neurons: it is the one 
projecting to the NAc. First of all, DA receptors antagonist (haloperidol) systemically injected 
in rodents blocks rewarding effects of food, amphetamine and cocaine, suggesting the 
implication of dopamine in these phenomena (Spyraki, Fibiger et al. 1982a; Spyraki, Fibiger 
et al. 1982b; Spyraki, Nomikos et al. 1987). Second of all, inactivation of DA neurons in the 
NAc by injecting 6-OHDA (a neurotoxin killing DA neurons) suppresses rewarding effects of 
cocaine or amphetamine (Roberts, Koob et al. 1980; Spyraki, Fibiger et al. 1982a). Thus, this 
evidence demonstrates that the dopamine tract from VTA to NAc is crucial for rewards 
effects mediation. Third of all, and as a confirmation, direct administration of dopamine 
receptors agonists in the NAc elicits reinforcing effects revealed by induction of CPP (White, 
Packard et al. 1991). Finally, rewarding action of morphine can also be observed by CPP after 
direct injection not in the NAc but in VTA (Phillips and LePiane 1980), suggesting the 
existence of distinct classes of drugs with different way of action (see § 1.1.5.). 
On the opposite side, people claimed that dopamine is not fully implicated in reward 
and that others dopamine-independent mechanisms can be involved. Indeed, in 2005, it has 
been demonstrated that CPP to morphine, we just cited above, was still present in dopamine 
deficient (DD) mice (Hnasko, Sotak et al. 2005). These animals generated by inactivating the 
tyrosine hydroxylase gene, coding for an essential dopamine synthesis enzyme, are unable to 
synthesize DA while the DA circuitry remained intact (Zhou and Palmiter 1995). A regular 
CPP for morphine in these animals suggests that dopamine is not implicated, at least for the 
induction of this behavioural response. In addition, a more recent paper showed a normal CPP 
to cocaine in DD mice (Hnasko, Sotak et al. 2007). Such evidence tends to prove, again, that 
DA release is not essential for this behaviour. Nevertheless, in the same paper, the authors 
clearly showed that serotonin mediates cocaine CPP in DD mice but not in wild-type animals. 
In other words, adaptive or compensatory changes in DD mice, probably during development, 
allow another monoamine, serotonin, to replace DA for assuming its functions in the reward 
effects mediation. Moreover, this CPP for cocaine was blocked by the DA type 2 receptor 
agonist quinpirole, showing that DA neurons activity is still required for CPP induction even 
if these cells are unable to release DA. Regarding these arguments, we can easily hypothesize 
that DA-independent CPP evoked by morphine in DD mice could also be explained by similar 
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developmental changes occurring in absence of DA. Taken together, these observations bring 
evidence for possible DA compensation instead of actual alternative mechanisms existing in 
physiological conditions. The following table gives an overview of the DA involvement in 
reward processes (Table 1) and the functions of the mesolimbic DA system will be exposed 
in more details in the next paragraph. 
 
Type of experiment Consequences Paradigm used 
Evidence for DA 
implication 
Systemic injection of 
DA antagonists 
No more rewarding 
effects of food, 
amphetamine and 
cocaine 
CPP Yes 
Destruction of DA 
neurons terminals             
(6-OHDA in NAc) 
No more rewarding 
effects of cocaine Self-administration Yes 
6-OHDA injection 
in NAc 
No more rewarding 
effects of amphetamine CPP Yes 
DA agonists injection 
in NAc 
Reinforcing effects CPP Yes 
Morphine VTA 
injection 
Reinforcing effects CPP Assumption 
Systemic injection of 
Morphine 
Reinforcing effects CPP Not in DD mice 
Systemic injection of 
cocaine 
Reinforcing effects CPP 
Not in DD mice due to 
adaptive changes.                          
Yes in physiological 
conditions. 
 
Table 1 Evidence for DA implication in reward effects mediation. DA = dopamine, CPP = conditioned place 
preference, NAc = nucleus accumbens, DD mice = dopamine deficient mice, 6-OHDA = 6-hydroxydopamine. 
 
1.1.4. The reward prediction-error hypothesis 
 
The theory for reward prediction-error is based on the innovative work from 
W. Schultz (Schultz, Dayan et al. 1997). In these in vivo experiments on non-anesthetized 
monkeys, the authors monitored the cellular activity of midbrain DAergic neurons. They 
showed a phasic activation of these neurons when a reward (R) occurs without any 
anticipation from the monkey (see Fig. 2). When they conditioned the animal to receive a 
reward, by applying a sensorial stimulus (CS = conditioned stimulus), the increase of DAergic 
cells activity appeared in synchrony with the CS but no more with the reward. Finally, when 
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the reward is expected but it is not delivered, the DAergic neurons of the VTA completely 
stopped their activity for a brief moment. To resume, the DA cells of the reward system do 
not code for the reward itself but for the prediction-error of the reward. In other words, this 
system makes the difference between what is expected and what you receive. If the prediction 
occurs, nothing changes, if not, a prediction-error signal is generated to update the prediction 
for the next time. The prediction-error can be assimilated to a learning signal carried by DA, 
able to induce changes in behaviour after activation of the areas targeted by mesolimbic DA 
neurons. 
 
 
 
Concerning the addictive drugs, it has been shown that all these substances use the 
mesolimbic dopamine system to mediate their rewarding/reinforcing effects (Wise 1996; 
Pierce and Kumaresan 2006). Indeed, their common point is their ability to increase the DA 
concentrations at the level of the NAc. Such enhancement in the DA release has been 
demonstrated, notably for amphetamine (Wise and Hoffman 1992), cocaine (Hurd, Weiss et 
al. 1989), opioids (Spanagel, Herz et al. 1992), cannabinoids (Cheer, Wassum et al. 2004), 
nicotine (Pontieri, Tanda et al. 1996) and ethanol (Weiss, Lorang et al. 1993). These 
Figure 2 Changes in dopamine neurons’ 
output code for an error in the prediction 
of appetitive events. In vivo recordings of 
mesolimbic DA neurons in a non-
anestetized monkey receiving or not (R or 
No R) a drop of juice with or without 
anticipation (CS or No CS) (from Schultz, 
Dayan et al. 1997). 
- 14 - 
 
observations give us a better understanding why drugs of abuse are implicated in addiction. In 
a normal situation, the mesolimbic DA system assures the coding of the reward prediction-
error, as we saw before. But, after drugs of abuse exposure, the DA transmission is shunted 
and all the areas targeted by the mesolimbic DA are stimulated in a exacerbate manner. In 
some cases, sustained DA release will evoke various and complex pathological modifications 
leading to addiction. Animal models of addiction are definitely helpful and powerful tools to 
understand the basic mechanisms induced by drugs of abuse. Nevertheless, we have to keep in 
mind that the processes underlying addiction are very complex. As a consequence they 
include aspects impossible to reproduce in animal models as sophisticated genetic changes or 
the influence of socio-cultural environment and so on. Finally, the diversity of substances of 
abuse, presented below, brings an additional level of complexity. 
 
1.1.5. Distinct classes of addictive drugs for distinct actions 
 
Since all addictive drugs mediate their effects via the same neuronal network and since 
they elicit a strong increase of DA release, it is not surprising that these chemically distinct 
substances may lead to the same disease: addiction. Nevertheless, regarding their broad 
biochemical diversity, it will be unexpected that all of them could target the mesolimbic DA 
system in a similar way. Actually, drugs of abuse can be arranged in three classes according 
to their mechanism of action (Luscher and Ungless 2006), as described below. 
The figure 3 illustrates the VTA microcircuit and its connexion with the NAc. The 
VTA is mainly composed by two neuronal populations, a majority of DAergic projecting 
neurons (Swanson 1982; Margolis, Lock et al. 2006b) under the inhibitory control of local 
GABAergic interneurons (Johnson and North 1992; Margolis, Lock et al. 2006a). Recently, a 
third population presenting a positive immunoreactivity for v-glut, a marker for glutamate, 
has been identified in the VTA (Yamaguchi, Sheen et al. 2007). However, precise functions 
concerning these neurons in addictive processes are currently unknown. On the other hand, 
actions on DAergic and/or GABAergic neurons of the VTA have been demonstrated for the 
majority of drugs of abuse. Morphine, cannabis and GHB can be arranged in the same class of 
addictive drugs (Class I) due to their ability to increase the DA release in an indirect manner 
after removing the inhibitory control of GABA cells (Johnson and North 1992; Cruz, Ivanova 
et al. 2004). Indeed, acting on their respective metabotropic Gi/o-protein coupled receptor 
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(GPCR), they suppress the GABAergic cells‟ activity resulting in a DAergic neurons 
disinhibition. In a similar way, addictive drugs belonging to the second class (Class II) are 
able to disinhibit DA neurons, increasing DA release in the NAc (see Fig. 3). Nevertheless, 
benzodiazepines, nicotine and ethanol are mediating their effects on ionotropic receptors or 
ions channels and are also capable to directly stimulate DA neurons (Maskos, Molles et al. 
2005). Finally, a third category of addictive drugs (Class III), composed of cocaine, 
amphetamine and ecstasy, directly acts on DA release at the level of the NAc. Instead of 
increasing the cellular activity of DA neurons to boost the DA release, these drugs target 
directly the DA transporters on axons terminal. Cocaine blocks the reuptake of DA by 
blocking its transporters increasing the concentrations of DA in the NAc (Chen, Tilley et al. 
2006). With amphetamine and ecstasy, the DA transporters are not blocked but reversed, a 
phenomenon that contributes to a similar DA accumulation in the NAc. 
 
 
Figure 3 The dominant targets involved in increasing dopamine for the major types of addictive drugs. G, Gi/o-
coupled receptors; i, ionotropic receptors/ion channels; T, monoamine transporters (from Luscher and Ungless 
2006). 
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Conscious that this classification is helpful to understand how a large diversity of 
drugs of abuse can induce similar addictive effects, it is primordial to study their specific way 
of action. One of the main aims of the addiction research is the development of therapeutic 
treatments. Because DA is implicated in so many mechanisms it is inappropriate to act 
directly on DA release. Conversely, specific knowledge on each addictive drug allows the 
design of specific and innovative therapy. In this report, we are focusing our attention on the 
GHB, an increasing popularity drug with addictive properties. In the past, our lab has already 
proposed that GHB could mediate its rewarding effects via a disinhibition of DA neurons as 
we saw above (Cruz, Ivanova et al. 2004). Here, we propose a molecular and cellular model 
of action for GHB (see RESULTS part). Based on this model, it may be possible to envisage 
clinical treatments to counter addictive behaviours. 
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1.2. The γ-hydroxybutyrate (GHB) 
1.2.1. History of GHB 
 
The γ-hydroxybutyrate was synthesized for the first time by Henri Laborit in 1960 
(Laborit, Jouany et al. 1960). GHB is a short fatty acid with a chemical structure similar to -
amino butyric acid (GABA, Fig. 4), endogenously present in mammalian brain (Bessman 
1963; Roth and Giarman 1970) and peripheral tissues (Maitre 1997) and capable of crossing 
the blood-brain barrier (Laborit, Jouany et al. 1960). It can be easily manufactured from its 
precursors, the -butyrolactone (GBL), a solvent notably present in cleaning products or from 
the 1,4-butanediol. GHB was investigated, at the beginning, as a general anaesthetic for 
surgery (Laborit, Buchard et al. 1960). But its capacity to rapidly induce a deep coma 
associated with minor cardiovascular and respiratory depression was counterbalanced by the 
evoked seizures episodes and its lack of analgesic effect (Vickers 1969). Thus, employment 
of GHB for this use has been dropped. 
 
 
Figure 4 The metabolic pathway of the -hydroxybutyrate (GHB) (from Drasbek, Christensen et al. 2006). Note 
that GHB can be obtained from two precursors (GBL and 1,4-butanediol) with established addictive potential. 
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1.2.2. GHB as a neurotransmitter 
 
Due to its chemical similarity to GABA, GHB is thought to be a putative 
neurotransmitter or neuromodulator of the mammalian central nervous system (Hosli and 
Hosli 1983). Levels of GHB, measured by gas chromatography, is heterogeneous in the 
mammalian brain and the highest concentrations were located in hippocampus, basal ganglia 
and midbrain (Maitre 1997). The neurotransmitter hypothesis was sustained by evidence 
describing the GHB Ca
2+
-dependent release following neuronal depolarization (Maitre, Cash 
et al. 1983). In these experiments, [
3
H]-GHB was loaded in brain slices and an efflux of 
radioactive GHB was observed after cellular depolarization. In addition, GHB uptake 
mechanisms were described highlighting an active transport of radioactive GHB across 
synaptosomal membranes (Benavides, Rumigny et al. 1982). Nevertheless, in physiological 
conditions, there is no evidence of such mechanism implicating endogenous GHB. Finally, a 
putative specific receptor for endogenous GHB has been cloned recently with high-affinity 
binding site for GHB (Andriamampandry, Taleb et al. 2003) reinforcing the idea that GHB 
can play a role as neurotransmitter or neuromodulator in the brain. We will see in more details 
in a next paragraphs that there is still a controversy regarding the receptor targeted by GHB in 
the brain (see § 1.2.6.). Indeed, GHB can bind another receptor, the -amino butyric acid type 
B receptor (GABABR). It seems that these distinct receptors mediate different effects of GHB 
in the brain. 
 
1.2.3. GHB as an addictive drug 
 
Previously, we saw that GHB is endogenously expressed in the mammalian brain. On 
the other hand, GHB has psychoactive and toxic effects when administrated in an exogenous 
form. It became popular in the 1990s at raves and nightclubs as an alternative to ecstasy and 
amphetamines. Its ingestion initially leads to euphoria (Lapierre, Montplaisir et al. 1990) but 
higher doses depress the level of consciousness up to a deep coma (Dyer 1991). Since the 
1990s in the US, reports on GHB illicit use let assume that this substance is addictive and for 
this reason it has subsequently be classified as a schedule I drug controlled by the FDA (Food 
and Drug Administration 1991; Galloway, Frederick et al. 1997). According to US laws, 
drugs and substances belonging to this family present a high potential for abuse and are not 
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accepted for medical treatment. In Switzerland, GHB sales are rigorously controlled since 
2001. Surprisingly, it is still possible to legally buy GBL, one of the GHB precursors. As a 
confirmation of the addictive potential of this compound, several studies showed that GHB 
can interact with the DAergic system which is primordial to mediate the rewarding effects of 
drugs of abuse and known to be altered in addiction. In this manner, GHB shows weak but 
observable reinforcing properties (Woolverton, Rowlett et al. 1999), only at low 
concentrations (Beardsley, Balster et al. 1996). Moreover, its rewarding properties were 
confirmed through conditioned place preference and self-administration paradigms 
(Martellotta, Fattore et al. 1997; Martellotta, Cossu et al. 1998) and the withdrawal syndrome 
it can evoke was well described (Galloway, Frederick et al. 1994; Tarabar and Nelson 2004). 
Paradoxically, GHB can, at the same time, decrease (Feigenbaum and Howard 1996; Raybon 
and Boje 2007) or increase (Feigenbaum and Howard 1996) the DA release in the brain. Cruz 
et al. have shown a dose-dependent bidirectional effect of the GABABR agonist baclofen in 
DA neurons of the VTA (Cruz, Ivanova et al. 2004). At low concentrations, baclofen inhibits 
the GABAergic interneurons that control the DA cells activity. This disinhibition increases 
the DA cells activity and subsequently the DA release in the NAc. Conversely, at higher 
concentrations, the DA neurons are directly inhibited. The authors suggested a similar 
mechanism for GHB. Thus, such possible bidirectional effect can easily explain why the GHB 
is used at the same time as a drug of abuse (lower concentrations) or as an anti-craving 
compound (higher concentrations), as shown in the next paragraph. Finally, note that some 
GHB precursors, as GBL and 1,4-butanediol, can be directly catalyze in GHB by our 
organism after ingestion and may be also consider as drugs with addictive potential 
(McMahon, Coop et al. 2003; Fig. 4). 
 
1.2.4. GHB for clinical therapy 
 
Several studies revealed that GHB can play a role as a clinical therapeutic agent. GHB 
was notably tested for the treatment of alcohol dependence (Fadda, Colombo et al. 1989; 
Gallimberti, Canton et al. 1989; Poldrugo and Addolorato 1999), where it produces a 
withdrawal reduction in a dose-dependent manner. Indeed, higher doses totally suppressed the 
ethanol withdrawal symptoms. Such suppression of withdrawal syndrome was also noticed in 
a study carried out on opioids addicts (Gallimberti, Cibin et al. 1993). Another evident 
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example has demonstrated, in rats, that GHB is also able to reduce cocaine self-administration 
(Martellotta, Balducci et al. 1998). In addition, GHB is also clinically administered to 
diminish the cataplexic patients‟ sleep episodes during the day and to improved the 
narcoleptic patients‟ sleep quality during the night (Broughton and Mamelak 1979). In this 
optic, a pharmacological company developed a medical treatment for narcolepsy called 
Xyrem®, a commercial name for the GHB molecule. 
 
1.2.5. Other known uses 
 
Many others functions have been attributed to GHB, sometime leading to inadequate 
applications. For example, GHB was reported to produce an increase in growth hormone as 
described by(Bluet-Pajot, Schaub et al.)in young rats and by(Van Cauter, Plat et al.)in young 
men but the mechanism is still poorly understood. Nevertheless, there is no clear evidence 
proving that GHB consumption reduces fat and builds muscles, thwarting the idea of certain 
bodybuilders, which abuse GHB as a food supplement. Moreover, GHB was described as a 
regulator of energy metabolism that may function as a protective agent during an excessive 
metabolic demand (Mamelak 1989). Finally, due to its sedative effect, GHB also evoked 
sexual disinhibition and for this reason it is unfortunately used as a „drug rape‟ (Stillwell 
2002). After GHB absorption, victims can fall asleep and an associated loss of short-term 
memory is often observed. In rape cases, prosecutions become difficult due to the fact that the 
victims do not remember exactly their aggression. 
By all these functions, GHB presents a large and complex panel of actions probably 
explained by its various targeted brain areas and/or the different used concentrations. In 
particular, distinct effects of GHB on the rewarding system described above seem to be dose 
and cellular type dependent. Because our lab‟s research is focusing on addiction, we were 
interested in decrypting the cellular and molecular mechanisms explaining the GHB aptitude 
to exert its effect on the reward system, processes still unknown. For the first time, it was 
precisely done during these thesis works (see RESULTS part). 
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1.2.6. GHB molecular targets in the brain 
 
Regarding the Literature, the GHB molecule could in theory interact with two distinct 
molecular targets: the GHB receptor (GHBR) and the -amino butyric acid type B receptor 
(GABABR). 
 
1.2.6.1. GHB receptor 
 
A few studies investigated the possibility that GHB can act on a specific receptor in 
the brain, called GHBR. In 2000, Snead sustained the idea that GHB could mediate its effects 
via a GHB-specific G protein-coupled receptor distinct from the GABABR (Snead 2000). In 
experiments performed in cortex preparations, 10 µM GHB was able to activate such receptor 
in a specific manner. Indeed, no GHB effect was detected in the presence of the specific 
GHBR antagonist NCS382. The receptor activation was dependent of a mechanism 
implicating Gi/o-proteins regarding the decrease in cyclic adenosine 3',5'-monophosphate 
(cAMP) concentration induced. However, these effects are only occurring in specific brain 
areas, like hippocampus and cortex and in the presynaptic compartment. Additional 
experiments based on [
35
S]GTPS binding assays, confirmed that G-protein activity can be 
activated in a GHB specific manner with a maximal effect at 250 µM. Taken together, these 
data let think that GHB can interact at low concentrations on a specific receptor (different 
from the GABABR) in certain brain areas. This receptor is apparently associated with a G-
protein activity but no evidence was brought for an intrinsic activity. However, concerning 
this GHB specific receptor, no more physiological or behavioral aspects have been tested. 
In addition, a more recent study described the cloning and the characterization of a 
56kDA molecule with seven putative transmembrane domains (Andriamampandry, Taleb et 
al. 2003). Receptor‟s sequence did not exhibit significant similitude with GABABR subunits 
sequences and the best match found gave a weak and inconsistent homology with a member 
of the tetraspanins superfamily. Regarding the lack of convincing similarity with existing 
sequences, GHBR identification remains an open question. However, the cloned GHBR 
showed a high affinity specific activation with GHB doses from 0.1 to 15 µM. The pattern of 
expression found for this receptor was quite similar to the one in the previous study, 
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indicating that the studied receptor was probably the same. Moreover, the authors claimed 
that this receptor has G-protein coupling capability (also demonstrated by GTPS binding 
assays) and no affinity for GABA, for the GABABR agonist baclofen or for glutamate was 
detected. Again, no evidence of a physiological GHBR-mediated activity was brought in this 
pure in vitro approach study using CHO transfected cells. 
 
1.2.6.2. -amino butyric acid type B receptor 
 
Concerning the second GHB target, the GABABR, it has been shown for a long time 
that GHB exerts ubiquitous pharmacological effects on the brain through this receptor. Thus, 
GHB binds to the GABABR (Xie and Smart 1992) where it acts as a weak partial agonist 
(Lingenhoehl, Brom et al. 1999). GABABR exhibits a low affinity binding site for GHB 
regarding the range of GHB concentrations necessary for its activation (from 0.25 to 10mM). 
Note that this range is much higher than the one required for the GHBR activation. In 
addition, some convincing evidence demonstrates that the implication of the GABABR is 
required to mediate most effects of exogenous GHB. Indeed, a study clearly proved that the 
major behavioral effects induced by GHB are absent in the GABABR1 subunit deficient mice 
(Kaupmann, Cryan et al. 2003). Moreover, this lack also included absence of effect on DA 
synthesis, normally observed in WT mice, suggesting that in GABABR1
–/–
 mice GHB lost its 
rewarding effects on the mesolimbic DA system. Finally, it is possible to mimic the 
pharmacological properties of GHB with GABABR agonists like baclofen, suggesting that this 
later and GHB act via GABABR in the same way (Shoaib, Swanner et al. 1998). 
To summarize, there is still controversy concerning the receptor mediating the GHB 
effects. However, the maximum endogenous concentration found in rat‟s adult brain 
approximates 5 µM while a rewarding dose of exogenous GHB will be responsible for a much 
higher concentration (about 20 fold more, see RESULTS part). In this optic, it is conceivable 
that GHB targets distinct receptors in a dose-dependent manner. As a confirmation, we saw 
that GHB at low concentration specifically binds GHBR (µM range) while higher 
concentration will activate GABABR (mM range). Conscious that some of the GHB effects 
and/or a part of the GHB signaling modulation could also be mediate by specific GHBRs, at 
least, the majority of the effects following an ingestion of GHB can be attributed to the 
GABABR. Thus, we focused our works on this receptor in the present report. 
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1.3. The -amino butyric acid type B receptor (GABABR) 
1.3.1. General GABABR properties 
 
The GABABR belongs to the huge ensemble of the GPCRs, more particularly to the 
family 3 in the GPCR classification (Bockaert and Pin 1999). The members of this subfamily 
exhibit sequence and structure similarities, as GABABR subunits, Ca
2+
 sensing receptor and 
metabotropic glutamate receptors. The main reported function of the GABAB receptor is the 
mediation of the GABA inhibition in the mammalian central nervous system (CNS), as we 
will see in a further paragraph. The GABABR is widely distributed in the brain of various 
vertebrate species, with highest levels in the hippocampus and cerebellum (Bettler, 
Kaupmann et al. 2004). GABABR has the particularity to be constituted by two distinct 
subunits, each one containing seven transmembrane domains (Fig. 5). The heterodimerization 
of the two subunits is a necessary step to form a functional receptor (Jones, Borowsky et al. 
1998; Kaupmann, Malitschek et al. 1998; White, Wise et al. 1998). Both subunits were cloned 
in 1997 (Kaupmann, Huggel et al.) and only the GABABR1 subunit apparently binds to 
specific antagonist at high-affinity (Kaupmann, Malitschek et al. 1998). As a confirmation, no 
pre and postsynaptic responses were observed in the GABABR1 deficient mice hippocampus 
after an application of baclofen (Schuler, Luscher et al. 2001). The receptor activation seems 
to be a complex process, nevertheless, a model of trans-activation was proposed where the 
ligand binds the GABABR1 subunit provoking a conformational change of the GABABR2 
associated subunit. This later is then able to couple the GABABR effectors for downstream 
signaling events (Galvez, Duthey et al. 2001). Such “coactivation” requires a colocalization of 
the two subunits and this is the case for the majority of the brain regions. However, it has 
been shown that the GABABR1 and GABABR2 transcripts are sometime expressed in distinct 
areas (Kuner, Kohr et al. 1999). It is difficult to see in these observations an independent role 
for GABABR1 or GABABR2, first of all, because the transcripts localization can differ a bit 
from the localization of the proteins coded by these mRNAs. Second of all, the GABABR1 
subunit requires the GABABR2 subunit to be expressed at the membrane. Indeed, it has been 
shown that the GABABR1 subunit is retained in the endothelial reticulum (ER) when 
expressed alone (Couve, Filippov et al. 1998). Additional expression of GABABR2 subunit 
allows the intracellular trafficking of GABABR1 from the ER to the plasma membrane 
(Marshall, Jones et al. 1999). Finally, two forms of GABABR1 subunits exist in the brain 
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bringing molecular diversity to this family of receptors. We will see how this diversity 
influences the GABABRs functional implication in a further paragraph (see § 1.3.3.2.). 
 
 
Figure 5 Model of the GABAB receptor heterodimer formed by association of the subunits GABABR1 and 
GABABR2. Experimental evidence have shown that only the GABABR1 subunit is able to bind at high affinity the 
GABABR specific antagonist CGP54626, while the GABABR2 subunit has the specificity to bind heteromeric G-
proteins (adapted from Marshall, Jones et al. 1999). 
 
1.3.2. GABABR activation by heterodimerization 
 
The heterodimer association between both GABABR subunits is required to obtain 
functional receptor. First evidence, the activation of the GABABR after a dimerization has 
been quantified in vitro in HEK293T cells (White, Wise et al. 1998). The binding efficacy for 
GABA measured after co-expression of both GABABR subunits corresponds to the high 
affinity one exhibited by the endogenous receptor present in the brain. These results suggest 
that GABABRs are heterodimers composed of GABABR1 and GABABR2 subunits. Jones et 
al. brought some complementary evidence leading to the same conclusion (Jones, Borowsky 
et al. 1998). The authors transfected fluorescent-tagged GABABR subunits and observed their 
subcellular localization with dual-wavelength confocal microscopy. A good overlay was 
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observed between subunits and their colocalization was confirmed by immunoprecipitation 
assays. In parallel, Kaupmann et al. looked at the cellular and subcellular distribution of the 
GABABR subunits via in-situ hybridation and electron microscopy and observed their 
colocalization at the level of dendritic spines (Kaupmann, Malitschek et al. 1998). Finally, the 
signal transduction evoked by the GABABR subunits heterodimerization was also investigated 
by these two last groups. They found a clear activation of the downstream GABABR 
effectors: the G-proteins and the GIRK channels. We will see later in this part what these 
effectors are and what are their role in the cellular processes, as those triggered by the GHB. 
 
1.3.3. GABABR signaling 
 
Once GABABR activated, notably with GHB, signaling processes will take place 
implicating different intracellular proteins, themselves able to trigger intracellular cascades or 
to interact with membrane effectors. These different steps are described below. 
 
1.3.3.1. The GABABR couples to Gi/o-protein 
 
After the binding of GABA, GHB or others agonists on GABABR, downstream events 
will be triggered through G-proteins. Indeed, it has been clearly established that the GABABR 
signaling is mediated by a Gi/o-protein activity. In 1984,(Wojcik and Neff)demonstrated that 
the GABABR was negatively coupled to adenylate cyclase in the brain suggesting that the 
receptor activation may trigger a signaling cascade playing on the cAMP production. 
Complementary works highlighted the possibility for the GABABR to bind guanosine-5'-
triphosphate (GTP) binding-proteins (Asano, Ui et al. 1985) or guanyl nucleotides (Hill, 
Bowery et al. 1984). Thus, the emerging idea for a G-protein implication became more and 
more evident. Moreover, additional evidence reinforced this idea by demonstrating that 
GABABRs predominantly couple to G-proteins. Different approaches like testing antisense 
oligonucleotides against Go-protein (Campbell, Berrow et al. 1993) were used and confirmed 
this hypothesis. Another obvious example consisted in a study in which the authors examined 
the selectivity of GABABRs to couple purified G-proteins in bovine brain membranes 
previously treated with N-ethylmaleimide, a compound used to inhibit GABA binding to 
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GABABRs (Morishita, Kato et al. 1990). Thus, they observed an increase in the GABA 
binding when purified Gi/o-proteins were added. The selective coupling efficiency to 
GABABR was reported to be dose-dependent and also determined by the type of G-protein  
subunit. In addition, the Gi/o-proteins that link GABABR have been described to be 
specifically sensitive to the pertussis toxin (PTX), a bacterial toxin able to ADP-ribosylate G-
proteins blocking their activity (Pfaffinger, Martin et al. 1985). Finally, these elements 
allowed people to propose a model where activation of GABABR is followed by the one of 
Gi/o-proteins. 
After the cloning of the GABABR, these features were confirmed by different in vitro 
approaches. For example, Kuner et al. looked for intracellular proteins that mediate signaling 
events downstream of GABABR1 activation (Kuner, Kohr et al. 1999). As a confirmation of a 
previously discussed point, they tested the GABABR activation after subunits 
heterodimerization and the implications of such phenomenon on the GABABR downstream 
signaling. In a yeast expression system, they deleted different amino acids sequences in the C-
term tail of GABABR1 and GABABR2 and found a specific interaction domain present in 
each subunit (Fig. 5, coiled-coil domain). This interaction only occurs with heterodimeric 
association, not between subunits of the same type. In addition, they proved that the 
heterodimerization of the GABABR elicited a decrease in forskolin-stimulated cAMP 
production, confirming the negative coupling of the GABABR to the adenylate cyclase cited 
previously. The cAMP production decrease was sensitive to PTX, proving the involvement of 
inhibitory Gi or Go proteins, sensitive to this toxin. Note that the cAMP production was also 
affected in the only presence of GABABR2 subunit, suggesting that the heterodimerization is 
not necessary at least for the G-protein activation by the GABABR2 subunit. This observation 
fits with the previous idea of a trans-activation of the GABABR where each subunit plays a 
specific role. Indeed, it has been shown that the GABABR1 subunit binds the ligand but 
doesn‟t activate the G-protein (Galvez, Parmentier et al. 1999; Galvez, Prezeau et al. 2000) 
while only the GABABR2 subunit is able to couple to G-proteins (Duthey, Caudron et al. 
2002; Kniazeff, Galvez et al. 2002). Finally, a genetic approach using mice lacking Go-protein 
 subunit also demonstrated a loss of coupling (Greif, Sodickson et al. 2000) that corroborates 
a specific GABABR/Gi/o-proteins interaction. 
At this level, it appears clear that all these approaches brought evidence of a specific 
coupling between the GABABR and the Gi/o inhibitory proteins. As illustrated in Fig. 6, the 
activation of GABABR leads to intracellular events after the dissociation of the heterotrimeric 
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Gi/o-protein between  subunit and  complex. At short term, the  complex will act on 
ionotropic channels present at membrane level, notably to regulate the cellular excitability. 
These mechanisms will be detailed afterwards in this report. Moreover, the activated  
subunit is able to trigger long-term events via intracellular cascade involving the adenylate 
cyclase, the cAMP and the protein kinase A (PKA). Briefly, the successive steps of inhibition 
initiated by the Gi/o-protein will evoke a decrease in the cAMP response element binding 
protein (CREB) phoshorylation. This ubiquitous transcriptional activator potentiates the 
transcription of many genes when phosphorylated. Thus, a decrease in its phosphorylation 
state will block the expression of specific genes. The parameters that determine which genes 
are targeted or not are various and complex as the cellular type, the cellular state, the type of 
receptors/G-proteins implicated, etc. 
 
 
Figure 6 Effectors pathways associated with Gi/o-protein coupled receptors. Binding of an agonist to GABABR 
leads to activation of a heteromeric Gi/o-protein and subsequent recruitment of second messenger pathway 
(cAMP) via the G-protein  subunit or ionotropic channels interaction via its  complex. 
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1.3.3.2. GABABR: Molecular and functional diversity 
 
Despite the fact that GABAB receptors are coded by a small family of homologue 
genes, they exhibit a certain molecular diversity. Each GABABR subunit is coded by a unique 
gene, however, it exists two identified forms of spliced variants for the GABABR1 subunit 
(Kaupmann, Huggel et al. 1997). These genes, called GABABR1a and GABABR1b, code for 
subunits that structurally differ by a pair of sushi repeats only present in the GABABR1a 
sequence (Blein, Ginham et al. 2004). The expression and the distribution of these different 
spliced variants were investigated in different papers. In the cerebellum, the GABABR1a 
isoform is early expressed during the development and localized presynaptically while the 
GABABR1b isoform is later expressed in postsynaptic compartments (Fritschy, Meskenaite et 
al. 1999). In addition, such specific subcellular distribution of GABABR subunits largely 
contributes to different cellular processes, as shown recently by Vigot et al. In hippocampal 
CA3 to CA1 synapses, they observed a specific asymmetric distribution of the GABABR1a/b 
subunits. GABABR1a subunits are predominantly expressed on the presynaptic side where 
they play a role in the inhibition of the glutamate release in association with GABABR2 
subunits. On the other hand, the GABABR1b subunits form heteroreceptors at postsynaptic 
locations, these later mediating the inhibition of this compartment (Vigot, Barbieri et al. 
2006). Such observations provide an evident link between the molecular diversity of 
GABABRs at distinct synaptic sites and their role in specific cellular functions (see Table 2). 
The next paragraph shows that distinct effectors are specifically associated to the 
GABABRs/G-proteins pre and postsynaptically. 
 
1.3.3.3. GABABR couples Ca
2+
 or K
+
 channels 
 
Previously, we saw that GABABRs have a broad distribution in the CNS with a 
specific composition along synapses. Moreover, the presynaptic population seems to be 
preferentially couple to voltage-sensitive calcium channels implicated in the neurotransmitters 
release. Indeed, the blockade of the calcium entry via N and P-type Ca
2+
 channels is mediated 
by the GABABR (Mintz and Bean 1993; Poncer, McKinney et al. 1997). When the GABABR 
is activated, the G complex will act at the level of the Ca2+ channels provoking their closure 
and stopping the intracellular calcium entry (Strock and Diverse-Pierluissi 2004). In addition, 
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the G-protein activated  subunit will trigger downstream events that directly block the 
priming of the vesicular neurotransmitter exocytose (Sakaba and Neher 2003). These 
processes both participate to the mediation of the presynaptic inhibition. On the opposite side, 
postsynaptically, the GABABRs are also implicated in the inhibition of neuronal transmission 
but they couple to distinct effectors: the G-protein gated inwardly rectifying potassium 
channels (GIRKs). In 1985, the possibility that GABABR can activate potassium currents has 
been demonstrated in hippocampus (Gahwiler and Brown 1985). More recently, it has been 
shown that this GABABR property is restricted to postsynaptic but not presynaptic 
compartments (Luscher, Jan et al. 1997). To resume, the GABABR couples distinct effectors 
depending on the cellular compartment where is expressed: voltage-sensitive Ca
2+
 channels or 
GIRKs on the pre or postsynaptic side, respectively. In addition, we saw previously the 
established molecular diversity of GABABRs in these compartments, suggesting a correlation 
between the receptor subunits composition and its cellular function. All these aspects were 
resumed and pooled in the following table. 
 
GABAB receptor 
subunit 
Assembly 
Predominant 
cellular 
localization 
Coupling Function 
GABABR1a 
Form 
heteroreceptors 
with GABABR2 
Presynaptic        
compartment 
To voltage-
sensitive Ca2+ 
channels 
Regulation of NT 
release and Ca2+ 
entry 
GABABR1b 
Form 
heteroreceptors 
with GABABR2 
Postsynaptic      
compartment To GIRKs channels 
Regulation of 
cellular excitability 
 
Table 2 Molecular and functional diversity of GABAB receptors. NT = neurotransmitter. 
 
As we focused our works on the molecular, cellular and physiological implication of 
GIRKs in the mediation of the GHB effects on VTA neurons, the present thesis report will 
mainly treat the later aspect of inhibition mediated by GABABR. Nevertheless, the majority of 
the knowledge concerning the GABABR cellular effects comes from the hippocampus. Thus, 
based on these observations, we propose a model explaining how GABABRs are implicated in 
the VTA network composed of GABA and DA neurons (Fig. 7). Finally, in the next part, 
entirely dedicated to GIRKs, the postsynaptic inhibition mediated by GABABR will be 
discussed in more details. 
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Figure 7 -Hydroxybutyrate (GHB) depresses presynaptic transmitter release and causes postsynaptic 
hyperpolarization at inhibitory synapses of the central nervous system (e.g. in VTA). Once activated by GHB, 
GABABR will trigger Gi/o-proteins able to inhibit voltage-sensitive Ca2+ channels or GIRKs depending of the 
cellular compartments. In VTA, postsynaptic cell consist in a DA neuron under the inhibitory control of a 
presynaptic GABAergic cell. 
- 31 - 
 
1.4. G-protein gated inwardly rectifying potassium channels 
 
As we saw before, the effectors of the GABABR in the brain are the G-protein gated 
inwardly rectifying potassium channels (GIRKs) or the voltage-sensitive Ca
2+
 channels 
depending on the considered subcellular compartment. Here, we focused our works on the 
GIRKs due to their implication in the regulation of VTA neurons activity that is primordial 
for the mediation of GHB rewarding effects. The properties of these channels are exposed in 
the next paragraphs (see also the RESULTS part). 
 
1.4.1. General GIRK channels properties 
 
The GIRK channels are rectifying voltage-independent ionotropic K
+
 channels (Kir3 
or GIRK family). In mammals, four subunits have been cloned: the GIRK1, GIRK2, GIRK3 
and GIRK4 subunit (Mark and Herlitze 2000). The distribution patterns of the GIRK subunits 
in the brain are quite similar but some areas like the VTA show differential GIRK 
composition (Karschin, Dissmann et al. 1996). GIRK1-3 subunits are the main subunits found 
in the brain, while GIRK4 is only weakly expressed (Wickman, Karschin et al. 2000). On the 
other hand, GIRK4 is predominantly expressed in the heart where it associates with GIRK1 
(Krapivinsky, Gordon et al. 1995). Moreover, GIRK5 subunits were only identified in the 
Xenopus laevis oocytes (Hedin, Lim et al. 1996). In the Literature, spliced variants were only 
described for the GIRK2 gene: the GIRK2a, b, c and d derivate from the alternative splicing 
of the GIRK2 mRNA at the 3‟-end of the open reading frame (Lesage, Duprat et al. 1994; 
Lesage, Guillemare et al. 1995; Tsaur, Menzel et al. 1995; Isomoto, Kondo et al. 1996; 
Inanobe, Horio et al. 1999). In comparison with others spliced variants, GIRK2c possesses a 
PDZ-binding motif in its C-terminal domain, as GIRK3, suggesting possible interactions with 
scaffolding proteins for channels recycling (Inanobe, Yoshimoto et al. 1999). A recent paper 
highlighted this kind of interaction by identifying a specific protein called SNX27 implicated 
in channels trafficking and able to link specifically the GIRK2c and GIRK3 PDZ-binding 
motif (Lunn, Nassirpour et al. 2007). Since others GIRK subunits, as GIRK1 and GIRK2a, 
form functional channels with GIRK2c and/or GIRK3, their surface expression can also be 
regulated in an indirect manner. We will discuss later the different assembling combinations 
of GIRK subunits and their associated function. 
- 32 - 
 
In addition, the fact that these K
+
 channels are rectifying represents one of their main 
feature. The rectification is due to a molecular interaction between the channel (pore), the 
intracellular charged polyamines and the K
+
 ions (Bichet, Haass et al. 2003). Indeed, in 
physiological conditions, when the GIRK channels are open, the potassium ions have the 
tendency to leave the cell due to the electrochemical gradient existing between the intra and 
the extracellular compartments, provoking a hyperpolarization of the cell (McCormick 1989). 
The polyamines, also positively charged, will compete with K
+
 ions. Due to their larger size, 
the polyamines will block the pore stopping the exit of potassium ions. To resume, the GIRK 
channels conduct K
+
 currents much more efficiently into the cell than out of the cell. As you 
can see on Fig. 8 below, the rectification of the GIRK channels is not complete at 
physiological conditions and it is still possible to elicit currents at these potentials (–50/–60 
mV). Note that the reversal potential for K
+
 in mammalian neurons is close to –100 mV. 
 
 
Figure 8 Rectification of GIRK channels revealed by I-V curve of maximal  opioid receptor agonist DAMGO-
elicited currents of a rat’s locus coeruleus (LC) neuron. I-V curve reverses at a potential close to the calculated EK 
(–106 mV) and shows typical inward rectification of GIRKs (adapted from Blanchet and Luscher 2002). 
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1.4.2. GIRK channels structure 
 
The GIRKs belong to the superfamily of channels composed of four subunits, each 
one containing two transmembranar segments (M1 and M2) flanked in between by a P-
domain (p-loop). When co-assembled, P-domain of each subunit participates to form a pore 
selective for K
+
 (Bichet, Haass et al. 2003). As represented in Fig. 9, the intracellular N and 
C-termini of a GIRK subunit is able to interact with numerous cellular molecules. 
 
 
Figure 9 Schematic representations of a single GIRK subunit and the identified regions responsible for G-protein, 
PIP2 and Na+/Mg2+ interactions. 
 
As previously described, GABABRs are coupled to inhibitory families of G-proteins 
(Gi/o), these later being able to trigger the opening of GIRK channels. Historically, it has been 
shown that the muscarinic acetylcholine K
+
 channel (KACh), later known to be composed by 
GIRK1 and GIRK4 subunits (Krapivinsky, Gordon et al. 1995) was activated by G-proteins 
(Logothetis, Kurachi et al. 1987). It was the first evidence demonstrating the GIRKs 
activation via an interaction with G-protein  complex. More recently, Huang et al. identified 
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the binding sites of this complex on the N and C-termini of GIRK channels (Huang, Slesinger 
et al. 1995; Huang, Jan et al. 1997; Fig. 9). The GIRKs-Gi/o interactions leading to channels 
activation are specific to PTX-sensitive G-protein-coupled receptors and are GTP-dependent. 
Indeed, innovative studies on single channel patch-clamp recording demonstrated that its 
activation is possible after intracellular application of GTP or with a GTP non hydrolysable 
analogue (GTPS). On the other hand, application of PTX that inactivate Gi/o-proteins or 
application of a GDP analogue which prevents GDP/GTP exchange (GDPS) suppressed this 
channel activation (Kurachi 1995). As presented below, others modulations at the GIRK 
channel level are also required for an optimal GPCR/G-protein signaling. 
Additional works focused on activation and deactivation of GIRK channels since a 
recent family of GIRKs modulators called regulators for G-protein signaling (RGS proteins) 
was identified. Indeed, these proteins showed abilities to strongly accelerate the kinetics of 
activation/deactivation proper to GIRKs (Doupnik, Davidson et al. 1997). These proteins also 
play a major role in the uncoupling between G-proteins  complex and the GIRKs. This later 
point will be further debated in the DISCUSSION part (§ 4.3.). Moreover, another type of 
GIRK modulation is carried out by phospholipids, notably by phosphatidylinositol-4,5-
biphosphate (PIP2). Indeed, a PIP2 application is sufficient to induce GIRKs activation in 
atrial myocytes or in oocytes from Xenopus, while PIP2 blockade using specific antibodies 
leads to the non-specific inhibition of all the inwardly rectified K
+
 channels (Sui, Petit-
Jacques et al. 1998). Such PIP2 treatment produces longer openings of GIRKs caused by a 
direct interaction with GIRKs C-terminus (Huang, Feng et al. 1998, Fig. 9). This kind of 
interaction only occurs in the presence of Na
+
 and Mg
2+
 ions which work in synergy with G 
and high concentrations of PIP2 to activate GIRKs (Petit-Jacques, Sui et al. 1999). These 
positive charged ions are able to neutralize on C-terminus a negative-charged aspartate 
residue allowing a stronger PIP2 binding (Ho and Murrell-Lagnado 1999). Na
+
 ions were also 
described to activate GIRKs in a G-protein independent manner by increasing their opening 
probability and by reducing their rundown (Sui, Chan et al. 1996). To resume, all these actors, 
in association, enhance the GIRK channels opening, binding their intracellular N and C-
terminal parts at different sites. Nevertheless, note that the time-scale for the phospholipids 
interaction is much slower than the one for the G interaction. 
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1.4.3. Pharmacology of GIRK channels 
 
The pharmacology permitting to interfere with the GIRKs is very poor and the 
majority of the available compounds have non-specific actions on these channels. Based on 
this observation, pharmacology is not so helpful to study GIRKs functions. However, a 
relatively selective GIRKs blocker exists: tertiapin (Jin and Lu 1998). This toxin, extracted 
from bee venom, is notably able to block the GIRK1/4 channels, binding the upper part of 
their pore region. The selectivity for GIRKs is not complete because this toxin will also act on 
ROMK1 channel (or Kir1.1), a K
+
 channel mainly expressed in the kidney. Currently, this 
toxin remains the only selective compound for a selective action against GIRKs in the brain. 
Others existing pharmacological tools permit to unselectively inhibit or activate GIRKs. In 
electrophysiology, the most used are barium (Ba
2+
), applied extracellulary, or intracellular 
cesium (Cs
+
), both able to block the pore of GIRKs (Lesage, Guillemare et al. 1995; Shieh, 
Coghlan et al. 2000). Inhibition of GIRKs can also be mediated by certain antipsychotics, 
antidepressants, anesthetics and so on, while some compounds are able to activate GIRKs, as 
ethanol, nitrous oxide, analgesics, etc. (Kobayashi and Ikeda 2006). Regarding the poor 
existing pharmacology for GIRKs, it appeared clear that others tools had to be developed in 
order to study the GIRKs implication in cellular processes. You will see in the RESULTS 
part that alternative approaches like transgenic GIRK knockout mice or molecular biology 
techniques can be also used for this purpose. 
 
1.4.4. GIRK channels assembly 
 
The manner by which GIRKs assemble is an important point considering that different 
GIRK composition could lead to different cellular properties with possible behavioral 
repercussion. Regarding the four GIRK subunits, it has been described that only some 
combinations are possible. In heterologous expression system, homotetramers GIRK2 and 
GIRK4 formed functional channels (Slesinger, Patil et al. 1996; Schoots, Wilson et al. 1999) 
while the others subunits, GIRK1 and GIRK3, have to be coexpressed with GIRK2 or GIRK4 
for an addressing to the membrane (Jelacic, Sims et al. 1999; Ma, Zerangue et al. 2002). To 
resume, the possible assembling combinations were tested for the three neuronal GIRK 
subunits: GIRK1, GIRK2 and GIRK3 that are detected in the brain, GIRK4 being weakly 
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expressed, as we saw previously. This study revealed that not all the combinations are 
possible, as demonstrated in a HEK cells expression system, where only a few are able to 
carry baclofen-evoked currents after GABABR coexpression (Cruz, Ivanova et al. 2004). 
Indeed, tetramer assembling of GIRK1/2, GIRK1/3, GIRK2/2 and GIRK2/3 were able to 
couple efficiently the GABABR while others combinations failed to display GIRKs currents. 
Several studies confirmed that the majority of these combinations are effectively expressed in 
the brain. GIRK1/2 heteromers were identified in cortical neurons and also in hippocampal 
neurons where they coexist with GIRK1/3 heteromers while GIRK2a/2c seems to be the 
predominant combination specifically found in neurons of the substantia nigra (Inanobe, 
Yoshimoto et al. 1999; Koyrakh, Lujan et al. 2005). Finally, in-situ hybridation technique 
revealed the presence of all the three GIRK subunits in hippocampus, suggesting that a mixed 
GIRK composition may exist in this structure (Koyrakh, Lujan et al. 2005). 
Concerning the area in which we are interested, the VTA, single cell RT-PCR assays 
have been performed, targeting the different GIRK subunits (Cruz, Ivanova et al. 2004). The 
GIRK composition was compared between the two main populations of the VTA: 
GABAergic versus DAergic neurons. GIRK1, GIRK2 and GIRK3 mRNAs were amplified 
from GABAergic cells while GIRK1 was lacking in DAergic neurons. According to the 
possible combinations found in HEK cells, the figure 10 represents the probable GIRKs 
assembling found in the VTA. Additional evidence let think that GIRK2 homotetramers are 
not present in DA neurons of VTA suggesting that these cells only express GIRK2c/3. First of 
all, in the same study, Cruz et al. observed a notable difference concerning the transfected 
GIRK2c/3 heterotetramers which exhibit a higher EC50 value than the one for GIRK2c 
homotetramers. This value corresponds to the concentration of GABABR agonist you need to 
apply to reach 50 % of the maximal GIRK evoked currents. A higher EC50 means a weaker 
coupling efficiency, indicating that this specific combination couples differently the 
GABABR/G-proteins. Second of all, transfections made in CHO-K1 cells to study the 
coupling efficiency between free  complexes and different GIRK channel compositions 
confirmed the particularity of the GIRK2c/3 heteromers. Indeed, the coupling efficiency of 
GIRKs for  was assessed and displayed sensitivity ~5 fold lower when GIRK2/3 channels 
were transfected in comparison with GIRK1/3 or GIRK1/4 (Jelacic, Kennedy et al. 2000). 
Such arguments suggest the predominant formation of GIRK2/3 channels in the DA neurons 
of the VTA. As a confirmation, a specific low coupling efficiency was observed in DA 
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neurons of the VTA in rats: the EC50 value for GABABR agonists was 10 fold higher in these 
cells when compared to GABAergic neurons. 
 
 
Figure 10 Schematic representation of GIRK channel subunit composition in VTA neurons. GABA neurons are 
probably composed by GIRK2 subunit homotetramers, GIRK1/3 or GIRK1/2 heterotetramers while DA neurons 
preferentially express GIRK2/3 heterotetramers. 
 
Which molecular diversity could explain the fact that DA neurons of the VTA have 
such different GABABR-GIRKs coupling? The present thesis works were carried out, in part, 
to answer this question. At present, we know that DA neurons constitute an exception in the 
brain since this is a unique example of weak coupling to GABABR. In fact, the GABABR-
GIRKs coupling efficiency reported for different cell types in the brain is higher than the one 
for DA neurons. According to their lower EC50 values, hippocampal CA1 neurons (Koyrakh, 
Lujan et al. 2005) and adrenergic cells of the locus coeruleus (unpublished data) exhibit a 
strong coupling efficiency closer to the coupling found in GABAergic neurons of the VTA 
(Cruz, Ivanova et al. 2004). In addition, all these cell types express both GIRK1, GIRK2 and 
GIRK3 subunit (Kawano, Zhao et al. 2004; Koyrakh, Lujan et al. 2005), reinforcing the idea 
that the low coupling observed in DA neurons is linked to their specific GIRK2c/3 
composition. Here, we performed experiments to verify the possible involvement of 
GIRK2c/3 heterotetramers in a weak coupling to the GABABR (see RESULTS part). 
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1.4.5. GIRK channels function 
 
What is the functional repercussion of the specific low GABABR-GIRKs coupling in 
DA neurons of the VTA? This question highlights another important point that we proposed 
to solve during this thesis. As general known functions, GIRKs play an essential role in the 
resting membrane potential control, in the cellular excitability regulation and also in the 
potassium homeostasis maintenance (Kubo, Baldwin et al. 1993; Reimann and Ashcroft 
1999). An example of a more specific function attributed to GIRKs is their well known 
implication in the heart rhythm regulation. Historically, it has been established that 
acetylcholine (ACh) evokes bradycardia and a decrease of heart contractility due to the 
hyperpolarization of the cardiac cell membrane (Loewi 1921; Del Castillo and Katz 1955). 
Later, it was proved that GIRK1/4 heterotetramers were responsible for this phenomenon, 
increasing the K
+
 efflux across the cardiac cell membrane under the influence of ACh 
(Krapivinsky, Gordon et al. 1995). In addition, we can list many specific GIRKs functions in 
the body because they are the effectors of many metabotropic receptors in various cell types 
and contribute to a wide range of physiological processes (Kobayashi and Ikeda 2006). 
Nevertheless, the functional implications of specific GIRK subunit compositions we are 
interested in are poorly understood, especially in the brain. Here we looked at the contribution 
of the specific GIRK subunit composition in the DA neurons of the VTA and its implication 
in the mediation of the GHB rewarding effects. 
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2. METHODS 
2.1. Mice 
 
The experimental procedures implicating mice were carried out with the permission of 
the Cantonal Veterinary Office of Geneva. Mice strains GIRK1
–/–
 (Bettahi, Marker et al. 
2002), GIRK2
–/–
 (Signorini, Liao et al. 1997), GIRK3
–/–
 (Torrecilla, Marker et al. 2002), 
Pitx3-GFP
+/–
 (Zhao, Maxwell et al. 2004) and GAD67-GFP
+/–
 (Tamamaki, Yanagawa et al. 
2003) were generated as described. The GIRK2
–/–
 GIRK3
–/–
 double knock-out strain was 
derived by breeding of GIRK3
–/–
 and GIRK2
+/–
 mice (Torrecilla, Marker et al. 2002). For all 
experiments, we used animals aged from 16 to 25 days, genders were balanced within groups 
and data were pooled because no differences in current amplitudes, desensitization and EC50 
were observed. 
 
2.2. Immunohistochemistry and pre-embedding immuno 
electron microscopy 
 
Wild-type mice and mice lacking various GIRK subunits were perfused with 4 % 
paraformaldehyde and 0.05 % glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). As 
described (Koyrakh, Lujan et al. 2005), three mice for each genotype were used and prepared 
for embedding in Durcupan resin blocks. From each of the 12 blocks, 3 ultrathin sections of 
the VTA were obtained (total of 36 sections, 70-90 nm thick) close to the surface of each 
block. Randomly selected areas were captured at a final magnification of 50,000X. For each 
subunit, we assessed gold particles in dendritic shafts, cell bodies, axons, and synaptic 
terminals of a reference area of approximately 2,000 µm
2
. More than 200 dendritic profiles 
per genotype were analyzed for each GIRK subunit. 
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2.3. Electrophysiology 
 
Horizontal slices (250 µm) of the midbrain were made from mice in cooled artificial 
cerebrospinal fluid (ACSF) containing (in mM): NaCl 119, KCl 2.5, MgCl2 1.3, CaCl2 2.5, 
NaH2PO4 1.0, NaHCO3 26.2 and glucose 11, bubbled with 95 % O2 and 5 % CO2. Slices were 
warmed to 34 °C and transferred after 1 h to the recording chamber, superfused with 
2.5 ml.min
-1
 ACSF. Visualized whole-cell voltage-clamp recording techniques were used to 
measure holding currents of neurons of the VTA at –63 mV. When recording from non-GFP 
mice, DA cells were identified by a large Ih current and by an outward current in response to 
the D2 receptor selective agonist quinpirole (20 µM), whereas GABA neurons showed no Ih, 
but produced an outward current in response to the µ-opioid selective agonist DAMGO 
(1 µM). The internal solution contained (in mM): potassium gluconate 130, MgCl2 4, 
EGTA 1.1, HEPES 5, Na2ATP 3.4, sodium creatine-phosphate 10, and Na3GTP 0.1. The 
calculated reversal potential for Cl
–
 was –71.7 mV. Currents were amplified, filtered at 1 kHz 
(Multiclamp 700B, Axon Instruments) and digitized at 5 kHz (National Instruments PCI-
MIO-16E-4 card) and saved on a hard disk (IgorPro v.5, WaveMetrics Inc.). Cell membrane 
and access resistances were monitored with each sweep and the experiment was terminated if 
the access resistance was outside the 10-25 MΩ range or changed by more than 20 %. Dose-
response curves were generated by applying either successively increasing concentrations of 
GABAB receptor agonists to the same cell or different concentrations to several cells. In the 
latter case the EC50 in DA neurons was 16.2 ± 1.8 µM (n = 8, not shown), in the former 
13.6 ± 0.3 µM (n = 10, not shown). This small underestimation was probably due to the 
desensitization that occurred in spite of the short duration of drug application. A Hill function 
was used to fit current amplitudes normalized to the maximal current obtained with a 
supersaturating concentration of the agonist. On these curves, each point represents the 
mean ± s.e.m. across all experiments. The corresponding bar graphs reflect the mean ± s.e.m. 
of all the EC50 values obtained in each cell. Epifluorescence with a U-LH100HG mercury 
lamp (Olympus) and two-photon imaging using a Ti-sapphire laser at the excitation 
wavelength of 900 nm (Spectra Physics) were used to visualize GFP-positive neurons. 
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2.4. In vivo gene delivery 
 
The mice (7-8g, about 3 weeks old) we used to deliver viral constructs in the VTA 
were anesthetized with ketamine (100 mg.kg
-1
) and xylazine (10 mg.kg
-1
), and placed in a 
stereotaxic frame (myNeuroLab). The Semliki Forest Virus (SFV, BioXtal) particles were 
injected (~0.5 µl, at least 10
8
 particles per ml) with a glass pipette (Drummond Scientific 
Company) bilaterally (antero-posterior –2.4 mm, lateral ±0.8 mm from bregma, and –4.4 mm 
from the surface). The virus was produced from RNAs that contained viral replication genes 
and the gene of interest linked to the GFP (transcriptional fusion to the amino terminus of the 
gene of interest under the SFV promoter (Sp6)). This plasmid together with a helper plasmid 
coding for structural proteins of the virus were then introduced by electroporation into BHK-
21 cells in order to produce viral particles. 
 
2.5. Behavioral assay for self-administration of GHB 
 
Mice (6 weeks old, 22-24 g) were habituated to get used to drinking from metal spouts 
attached to two 450 ml plastic bottles in their home cage and handling for one week where 
they had unlimited access to water. One day before the test, 4 % sucrose was added to both 
bottles. For four days, mice then had access to bottles containing either GHB in sucrose or 
sucrose alone. To determine GHB preference or aversion, we calculated the difference of 
consumption between the GHB solution and the control solution (Δ Volume = consumption of 
GHB with sucrose solution minus consumption of sucrose solution). One cage was excluded 
from the analysis because of a marked fluctuation in the total volume consumed. 
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2.6. Reagents 
 
All the drugs are supplied by Tocris except Morphine-HCl from Amino AG or from 
the pharmacy of the university hospital of Geneva. Rabbit anti-GIRK1 and anti-GIRK2 
antibodies were obtained from Alomone Labs. An affinity-purified rabbit anti-GIRK3 
antibody was raised against a residue of 36 amino acids corresponding to the carboxy terminal 
of GIRK3. The monoclonal antibody anti-TH was obtained from Calbiochem. 
 
2.7. Statistics 
 
Compiled data are expressed as mean ± s.e.m. For statistical comparisons of two 
conditions, the nonparametric Mann-Whitney test was used (Instat 3.0, Version GraphPad 
Inc.). For multiple comparisons, a two-way ANOVA followed by Bonferroni or Fisher post-
test or the non-parametric Kruskal-Wallis Test followed by Dunn's post tests were applied. 
The levels of significance are indicated as follows: 
***
P < 0.001, 
**
P < 0.01, 
*
P < 0.05. 
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3. RESULTS 
 
The works carried out during my thesis have succeeded in a first author contribution in 
a Nature Neuroscience journal publication. This article entitled “RGS2 modulates coupling 
between GABAB receptors and GIRK channels in dopamine neurons of the ventral 
tegmental area” was published in the December 2007 issue of this journal. All the results 
presented in this report are those in which I brought an entire or, at least, a major contribution. 
 
3.1. Baclofen-evoked currents in VTA neurons 
 
We measured the EC50 value for GIRK currents elicited by baclofen to estimate the 
coupling existing between the GABABR and GIRK channels in VTA neurons of mice. We 
took advantage of transgenic lines that express green fluorescent protein (GFP) in defined 
types of VTA neurons. This approach is more reliable than the identification of DA and 
GABA neurons previously used in rat slices, which was based on the presence of Ih currents 
and their response to µ-opioid and D2 receptor agonists, criteria that have been challenged 
recently (Ford, Mark et al. 2006; Margolis, Lock et al. 2006a). In the first mouse line, GFP 
was selectively expressed in cells that express Pitx3, a transcription factor that is required for 
the development of DA neurons of the midbrain (Wallen and Perlmann 2003) and therefore is 
selectively expressed in these neurons, as confirmed with immunohistochemistry for tyrosine 
hydroxylase (TH) (Zhao, Maxwell et al. 2004). The second strain was a glutamate 
decarboxylase 67-GFP (Δneo) mouse, here called GAD67-GFP mouse for simplicity 
(Tamamaki, Yanagawa et al. 2003), in which GFP is selectively expressed in GABA neurons. 
Therefore, in heterozygous mice of either line, specific types of neuron are fluorescent and 
can be easily identified (Fig. 11a, b). Patch-clamp recordings in Pitx3-GFP-positive neurons 
revealed large Ih currents and desensitizing baclofen-evoked currents (Fig. 11a). In most 
cases, the GAD67-GFP phenotype did not show an Ih current and baclofen-evoked currents 
did not desensitize (Fig. 11b). GFP-negative cells in GAD67-GFP mice behaved like DA 
neurons, whereas GFP-negative neurons in Pitx3-GFP mice showed currents that resembled 
those of GABA neurons (Fig. 11c, d). In fact, in GFP-negative cells the maximal baclofen-
evoked current (GABA neurons 45 ± 15 pA for GFP-negative cells versus 44 ± 15 pA for 
GFP-positive cells; DA neurons 186 ± 44 pA versus 151 ± 26 pA; Fig. 11e) and its 
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desensitization, (GABA neurons 89 ± 11 % versus 89 ± 10 %; DA neurons: 55 ± 3 % versus 
63 ± 5 %; Fig. 11e) did not differ from those of corresponding GFP-positive cells. Successive 
brief applications of increasing concentrations of baclofen elicited responses that were 
normalized to the maximal response obtained with a supramaximal concentration. These 
responses were used to construct dose-response curves and to calculate the EC50 in both 
mouse lines (GABA neurons 1.5 ± 0.1 µM for GFP-negative cells versus 1.2 ± 0.1 µM for 
GFP-positive cells; DA neurons: 12.6 ± 1.1µM versus 14 ± 1.6 µM; Fig. 11f, g). Thus, we 
confirm that in mice, just as in rats (Cruz, Ivanova et al. 2004), the EC50 for GIRK channel 
activation by GABAB receptors is about an order of magnitude higher in DA neurons than in 
GABA neurons in the VTA. 
Our data also reveal that the Hill coefficient is slightly larger in DA neurons than in 
GABA neurons (1.3 ± 0.2 versus 1.0 ± 0.03, average of both genotypes, P < 0.05; Fig. 11h). 
This difference is probably due to the desensitization of the GIRK currents, which is larger in 
DA neurons than in GABA neurons. Even with short baclofen applications, we cannot 
exclude the possibility that a small underestimation of the current amplitude in DA neurons, 
when normalized to the maximal response, would make the concentration-response curve 
look steeper. In fact, throughout our study, we observed similar differences for the Hill 
coefficients in experiments where desensitization was affected by the manipulation. 
Importantly, any underestimation of the amplitude measurements due to desensitization 
would lead to a slightly smaller EC50 value in the control condition, and therefore to a small 
underestimation of the difference (see METHODS). 
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Figure 11 Baclofen-evoked currents in DA and GABA neurons of the VTA.(a) Top, visualization of GFP-positive 
VTA neurons in a slice from a Pitx3-GFP+/– mouse. Images were obtained in the fluorescent (left) and transmitted 
(right) light channels of a two-photon laser-scanning microscope. White and black arrows point to the recorded 
neuron. Bottom, representative whole-cell traces obtained in this neuron. A hyperpolarizing pulse evoked an Ih 
current (left); the right panel shows a typical response to baclofen (baclo; 100 µM). Currents were reversed by the 
selective antagonist CGP54626 (2 µM). (b) Visualization (top) and whole-cell recordings (bottom) obtained in a 
GABA neuron identified by GFP-fluorescence in the VTA of a GAD67-GFP+/– mouse. (c,d) Recordings obtained in 
GFP– neurons from a GAD67-GFP+/– and a Pitx3-GFP+/– mouse, respectively. Currents strongly resemble the 
recordings in a,b so the cells are probably DA and GABA neurons, respectively. Scale bars for bottom left panels, 
300 ms / 200 pA; for right panels, 2 min / 50 pA (DA neurons) 25 pA (GABA neurons). (e) Normalized residual 
current against initial maximal amplitude of current evoked by 10 min baclofen (100 µM). In both mouse lines, 
currents in DA neurons (n = 8) were significantly larger and showed stronger desensitization than in GABA 
neurons (n = 9). (f) Bar graph representing EC50 values from DA neurons (filled bars) and GABA neurons (empty 
bars) in GAD67-GFP and Pitx3-GFP mice. (g) The EC50 values were derived from concentration-response curves 
for baclofen-evoked currents in GABA neurons (n = 7) and DA neurons (n = 8) in both genotypes. (h) Hill 
coefficient derived from the dose-response curves in GABA and DA neurons obtained in slices from both mouse 
lines. 
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3.2. Cell-type specific GIRK subunit expression 
 
We next combined immunohistochemistry for TH with immunogold labeling for 
GIRK subunits in ultrastructural experiments that were designed to visualize the subcellular 
distribution of GIRK subunits in the VTA. This high-resolution technique revealed that 
GIRK1 is present only at extrasynaptic sites in TH-negative dendrites (Fig. 12a, b), whereas 
GIRK2 and GIRK3 were found at extrasynaptic sites in both TH-positive and TH-negative 
cells (Fig. 12d, e, g, h). Immunogold labeling for GIRK1, GIRK2 and GIRK3 was absent in 
GIRK1
–/–
, GIRK2
–/–
 and GIRK3
–/–
 mice, respectively, confirming the specificity of the 
antibodies used for electron microscopic staining (Fig. 12c, f, i) and of the GIRK3 antibody 
that was used in this study for the first time for light microscopy (Fig. 12j, k, l). These 
observations extend our previous analysis of cell-type specific GIRK subunit expression in 
the VTA, which was carried out using single-cell PCR with reverse transcriptase (RT-PCR, 
Cruz, Ivanova et al. 2004), and confirm that GIRK1 is selectively expressed in TH-negative 
neurons while GIRK2 and GIRK3 are found in both TH-positive and TH-negative cells. 
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Figure 12 Cell-type specific subcellular localization of GIRK subunits. Pre-embedding electron micrographs 
combining immunoperoxidase (HRP) staining for TH and immunogold (gold) labeling for GIRK1, GIRK2 or GIRK3 
in the VTA. (a) Immunoparticles for GIRK1 were observed along the extrasynaptic plasma membrane (arrows) of 
dendritic shafts that were immunonegative for TH (Den). Peroxidase reaction product (immunoreactivity for TH) 
filled dendritic shafts (Den, TH+), which were devoid of immunoreactivity for GIRK1. (b) The selective presence of 
GIRK1 in TH– neurons is consistent throughout serial sections. (c) GIRK1 immunogold labeling is abolished in 
GIRK1–/– mice. (d,e,g,h) Similar images obtained with immunolabeling for GIRK2 and GIRK3, respectively, reveal 
that these GIRK subunits are found along the extrasynaptic plasma membrane (arrows) of dendritic shafts of TH– 
and TH+ cells (crossed arrows). (f,i) Absence of GIRK2 and GIRK3 labeling in GIRK2–/– and GIRK3–/– mice, 
respectively. Ax, axon terminals. Scale bars, 0.2 µm. (j-l) Light-microscopic immunoreactivity in slices from wild-
type mice (two examples at different magnification) and example in GIRK3–/– mouse. Scale bars, 1 mm. 
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3.3. Baclofen-evoked currents in mice lacking GIRK subunits 
 
We subsequently tested the involvement of GIRK1-3 subunits in baclofen-evoked 
currents in GIRK1
–/–
, GIRK2
–/–
, GIRK3
–/–
 and GIRK2
–/–
 GIRK3
–/–
 double-knockout mice in 
neurons of the VTA. Previous studies have shown that baclofen activates, in addition to GIRK 
channels, a Ba
2+
-resistant conductance whose molecular identity remains unknown, but that 
shows some of the pharmacological properties of two-pore K
+
 channels (Torrecilla, Marker et 
al. 2002; Cruz, Ivanova et al. 2004). Here, we used in our experiments the Ba
2+
-insensitive 
conductance as a reference, which had the advantage of reducing the variability caused by the 
size of the cell. We measured the amplitude of the Ba
2+
-insensitive current component by 
applying Ba
2+
 (1 mM) before antagonizing GABAB receptors (Fig. 13a, d). The Ba
2+
-
insensitive component did not differ across all knockout mice tested in both VTA cell types 
(Fig. 13b, e), confirming that it is not carried by GIRK channels. For each cell, the amplitude 
of the Ba
2+
-insensitive current was divided by the maximal current. This ratio was then 
subtracted from 100% to calculate the relative GIRK component. DA neurons exhibited 
currents unaltered in GIRK1
–/–
 mice (79 ± 5 % versus wild-type 84 ± 4 %), virtually abolished 
in GIRK2
–/–
 mice (8 ± 6 %, P < 0.001) and GIRK2
–/–
 GIRK3
–/–
 mice (4 ± 5 %, P < 0.001), 
and slightly but significantly reduced in GIRK3
–/–
 mice (73 ± 5 %, P < 0.05; Fig. 13c). 
Together, these results indicate that GIRK2 and GIRK3 contribute to endogenous currents in 
DA neurons, indicating that these neurons contain GIRK2/3 heteromers. Although the lack of 
GIRK3 can be compensated partially (presumably through the formation of GIRK2 
homomers), this is not possible after knockout of GIRK2. 
Concerning the GABA neurons, the situation is more complex due to the endogenous 
coexpression of three subunits that leads to more possible GIRK channels combinations. 
Nevertheless, the GIRK currents profiles obtained were quite similar to those in DA neurons. 
Values after deletion of GIRK1 (68 ± 3 % versus wild-type 77 ± 2 %, P > 0.05) or GIRK3 
subunit (66 ± 4 %, P > 0.05; Fig. 13f) suggest that compensatory channels formation occurs 
allowing the restoration of currents as closed as they are in wild-type. On the other hand, this 
is not the case in GIRK2
–/–
 GIRK3
–/–
 mice where currents are totally abolished (no detectable 
currents, P < 0.001; Fig. 13f). These results are consistent with the previous observation 
where GIRK1 cannot be addressed alone at the membrane (Ma, Zerangue et al. 2002). 
Interestingly, the striking difference between VTA neurons consists in the persistence of 
GIRK currents in GABA neurons after GIRK2 deletion. Indeed, while in these cells GIRK1/3 
- 49 - 
 
channels can probably still be formed (Cruz, Ivanova et al. 2004), in DA neurons there is no 
compensation due to the absence of GIRK1 and the impossibility for GIRK3 to form 
homotetramers (Jelacic, Sims et al. 1999). 
 
 
 
Figure 13 Contribution of GIRK channel subunits to total outward current in neurons of the VTA. (a,c) A large 
fraction of the baclofen-evoked current (100 µM) is inhibited by BaCl2 (1 mM) in wild-type (WT) mice. Subsequent 
reversal with CGP54626 reveals the Ba2+-resistant component of the current. Scale bars, 50 pA / 2 min. (b,e) The 
Ba2+-resistant component was of similar magnitude in all the GIRK–/– mice tested. (c,f) Fraction of GIRK currents 
obtained by normalization to the Ba2+-resistant component in DA or GABA neurons in all the genotypes. 
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3.4. EC50 is determined by GIRK subunits in DA neurons 
 
In order to study the implication of GIRK subunits in the coupling efficiency to the 
GABABR, we developed in our lab a technique of in vivo stereotaxic viral gene delivery. In a 
first step, we tested the impact of expressing empty Semliki Forest vectors (GFP alone) in 
VTA neurons. As expected, we did not observe any changes between transfected GFP-
positive DA neurons and untransfected cells regarding baclofen-evoked currents (amplitude: 
206.8 ± 69.8 pA versus 261.5 ± 39.6 µM pA; desensitization: 54.8 ± 2.5 % versus 
50.8 ± 2.5 %, P > 0.05; Fig. 14a) or EC50 values (17.8 ± 4.1 µM versus 16.3 ± 3.1 µM, 
P > 0.05; Fig. 14b). 
 
Figure 14 Electrophysiological properties of DA transfected neurons. (a) Baclofen-evoked currents mesured for 
10 min agonist application and reversed by the selective antagonist CGP54626 in a DA neuron transfected (red 
symbols) by Semliki Forest Viruses expressing GFP or in untransfected (black symbols) DA neuron. Vertical bar 
represents 50pA. (b) Concentration-response curves are shown for transfected (circles, n = 12) and untransfected 
DA neurons (triangles, n= 5). Both conditions tested in the same animals (unpublished data). 
- 51 - 
 
As GIRK2/3 heteromeric channels show a lower affinity for Gβγ-dimers than do other 
GIRK subunit combinations and because GIRK2c/3 heteromers expressed in HEK293 cells 
show a higher EC50 for activation by baclofen (see INTRODUCTION, § 1.4.4.), we 
predicted that the EC50 for baclofen-evoked currents in DA neurons of GIRK3
–/–
 mice would 
be lower than in wild-type mice. In fact, we found a value of 7.4 ± 1.2 µM, which was 
significantly lower than in neurons from wild-type mice (14.2 ± 1.3 µM, P < 0.01; Fig. 15a, 
b). Because DA neurons lack GIRK1, we postulated that ectopic expression of GIRK1 might 
shift the EC50 to lower concentrations. We injected a viral vector harboring GIRK1 and GFP 
into the VTA. As expected, in transfected DA neurons, baclofen yielded currents with a 
significantly lower EC50 than in neighboring untransfected cells (6.5 ± 1 µM versus 
14 ± 1.2 µM, P < 0.001; Fig. 15c, d). 
We next investigated whether the type of GPCR helped to determine the low coupling 
efficiency with GIRK channels. We expressed another pertussis toxin-sensitive Gi/o-coupled 
GPCR, the µ-opioid receptor (MOR), in DA neurons using a viral construct. Normally MORs 
are selectively expressed on GABA neurons of the VTA. The recombinant MORs expressed 
in DA neurons reliably coupled to GIRK channels, producing an EC50 for morphine-induced 
GIRK currents that was significantly higher than in GABA neurons (206 ± 19 nM versus 
56 ± 4 nM, P < 0.01; Fig. 15e, f). These results show that the EC50 for GPCR activation of 
neuronal GIRK channels is determined by the subunit composition of the GIRK channel and 
does not depend on the identity of the GPCR. 
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Figure 15 GABAB-GIRK coupling efficiency in DA neurons is determined by GIRK subunit expression. (a) 
Concentration-response curve to baclofen in DA neurons of GIRK3–/– mice (n = 8) compared to DA neurons of 
wild-type mice (n = 8). (b) Mean of the EC50 value calculated for each cell. (c) Concentration-response curve of 
baclofen-evoked currents in GIRK1-GFP transfected DA neurons (green cells, inset; n = 9) and neighboring 
untransfected DA neurons (as determined by the presence of Ih and response to D2 receptor agonist) in wild-type 
mice (n = 8). (d) EC50 values for neurons in c. (e) Concentration-response curve for morphine in MOR-GFP 
transfected DA neurons (green neurons, inset; n = 6) and untransfected GABA neurons (absence of Ih and 
response to MOR agonist) in wild-type mice (n = 6). (f) Mean EC50 values from e. 
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3.5. Effects of GABABR agonists on DA cells activity 
 
We previously saw that all drugs of abuse target the mesolimbic dopamine system 
conducting to a common increase in the DA release (see INTRODUCTION, § 1.1.5.). Here, 
we were particularly interested in understanding how GHB could evoke such phenomenon. 
We know that GHB mediates its rewarding effects via the GABABR and we have just 
discovered that this receptor differently couples the GIRK channels in VTA neurons. What is 
the functional repercussion of such different coupling on the mediation of GHB effects? To 
answer this question, here we used an in vitro approach and looked for the first time at the 
GHB effects on the cellular activity of VTA neurons. While monitoring the firing frequency 
in connected DA neurons, we applied a low concentration of GHB, which led to a frequency 
increase in slices from wild-type mice (Fig. 16a). On average, the firing frequency increased 
to 162 ± 13 % with a GHB concentration of 0.1 mM (P < 0.01; Fig. 16b). Applying 10 mM 
GHB completely suppressed firing (11 ± 3 %; 16a, b) of DA neurons. The effect of GHB was 
reversed by the GABAB receptor antagonist CGP54626 (105 ± 3 %; Fig. 16a, b). Like the 
effects of GHB, the disinhibition was also observed with a low concentration of baclofen 
(177 ± 9 % P < 0.01; Fig. 16c, d), confirming what was shown previously in rats (Cruz, 
Ivanova et al. 2004). Regarding our previous observations, we can now claim that the 
magnitude of the shift in the dose-response curves between VTA neurons determines the 
concentration window in which GHB can lead to DA neurons disinhibition. In other words, 
the uncoupling found in DA neurons is primordial for the mediation of GHB rewarding 
effects and explains its bidirectional effect on DA neurons observed here. 
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Figure 16 Bidirectional effect of GABAB receptor agonists on the firing rate of DA neurons in the VTA. (a) Single-
spike activity (top) recorded in cell-attached configuration (10 s duration) from a wild-type DA neuron at 
corresponding time points of the lower trace showing the spiking frequency as a function of different GHB doses. 
Effect of GHB was reversed by CGP54626 (2 µM). (b) Mean of basal frequency (top). Relative change in average 
firing frequency (bottom, n = 5). (c,d) Similar experiment as in a and b carried out with baclofen (n = 6). In all 
experiments excitatory inputs were blocked with kynurenic acid (2 mM). 
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3.6. Modulation of GABAB-GIRK coupling by GHB 
 
We have shown that acute effects of -hydroxybutyrate lead to the disinhibition of 
VTA DA neurons due to a specific GIRK subunit assembly. Here, we further investigated the 
others possible effects of GHB on the reward system. 
In the context of drug abuse, it has been reported that in response to chronic drug 
exposure, the expression of certain proteins implicating in the coupling between GPCRs and 
GIRK channels, as RGS (see DISCUSSION, § 4.3.), can change (Traynor and Neubig 2005). 
Thus, we predicted that a chronic GHB treatment could exert a profound impact on coupling 
between GABAB receptors and GIRK channels. We therefore injected the mice twice daily 
with GHB (250 mg.kg
-1
) for 5 days and prepared slices 1 h after the last injection on the 
morning of the 6th day. In these conditions, the EC50 was significantly lower than in slices 
from untreated mice (6.1 ± 0.2 µM versus 12.3 ± 0.2 µM, P < 0.001; Fig. 17a, b). To test 
whether changes in coupling could also be elicited by chronic exposure to other addictive 
drugs, we injected increasing doses of morphine (20-100 mg kg
-1
 twice daily) over 6 days. In 
slices prepared from these mice 2 h after the last morphine injection, the EC50 for baclofen-
evoked currents in DA neurons was significantly lower than in slices from saline-treated mice 
(8.8 ± 1.2 µM versus 13.2 ± 0.7 µM, P < 0.01; Fig. 17b). 
We next tested whether prolonged in vitro exposure of the slice to morphine was 
sufficient to alter GABAB-GIRK coupling. We incubated slices for 5 h in morphine (5 µM) 
and found a similar reduction in the EC50 (6.5 ± 0.3 µM versus 14 ± 1 µM; Fig. 17c, d). 
Together, these results indicate that chronic exposure to GHB or morphine causes an increase 
in the coupling efficiency to GIRK channels, probably by regulating the expression level of 
proteins responsible for the modulation of this coupling (see DISCUSSION, § 4.3.). Such 
mechanisms are conserved despite the different nature of GPCR implicated. Finally, after a 
chronic GHB treatment, the shift in EC50 predicts that a new GHB application will exert a 
smaller effect of disinhibition on DA neurons. 
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Figure 17 Chronic exposure to GHB and morphine modulates GABAB-GIRK coupling efficiency in DA neurons of 
VTA. (a) Concentration-response curve of baclofen-evoked currents in DA neuron in mice treated with chronic 
GHB (n = 7) versus chronic saline (n = 6). (b) Mean EC50 values of baclofen-evoked currents in DA neurons of 
mice treated with GHB, morphine and saline (n = 6-7). (c) Concentration-response curve obtained in slices that 
were incubated 5h in morphine (square, n = 13) or regular ACSF (n = 8) for 5 h. (d) EC50 values obtained in the 
same conditions. 
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3.7. Chronic GHB alters preference for self-administration 
 
In DA neurons from the VTA, we have shown that chronic treatment with GHB 
increases the coupling efficiency of GABAB receptors to GIRK channels. As a consequence 
of this lower EC50, we predicted that GHB would lose its rewarding properties, and might 
become aversive. To test this, we investigated the preference for GHB in an oral self-
administration assay after chronic injections of GHB (250 mg.kg
-1
 intraperitonally twice daily 
for 5 days, as for Fig. 17). 
First, to determine the concentration that would be most preferred, mice were offered a 
choice between bottles containing GHB (0.001 % to 1 %) mixed with 4 % sucrose or sucrose 
alone. Sucrose was added to mask possible taste-related preference or aversion for GHB. At 
low concentrations (0.001 % and 0.01 %), mice drank more from the GHB-containing bottle 
than the control bottle (Δ volume over 4 days for GHB 0.001 %: 12.5 ml, for 0.01 %: 16.1 ml, 
for 0.1 %: 3.2 ml, or for sucrose alone: 0.4 ml), whereas at higher concentrations mice 
avoided the GHB-containing bottle (GHB 1 %: –21.2 ml; Fig. 18a). These results reflect, at 
the behavioral level, the bidirectional effect of GHB previously observed in vitro. Low GHB 
concentrations allow the mediation of its rewarding effects (preference) while high 
concentrations abolish them (aversion). 
As GHB at 0.01 % was the most preferred solution, it was used for the subsequent 
measurements of drinking preference after chronic injections of GHB. Although the total fluid 
consumption during the four-day test period did not differ between the two groups (saline: 
64.9 ± 11.4 ml versus GHB: 68.9 ± 11.3 ml, P > 0.05; Fig. 18c), saline-injected mice showed 
a preference and GHB-injected mice an aversion for the 0.01 % GHB solution over four days 
(1.0 ± 1.3 ml saline versus 15.0 ± 5.8 ml GHB and 0.9 ± 1.3 ml saline versus –6.3 ± 2.2 ml 
GHB, respectively, P < 0.05; Fig. 18b). These behavioral experiments establish a link 
between the efficiency of coupling of GABAB receptors with GIRK channels in the VTA and 
the behavioral response to the addictive drug GHB. 
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Figure 18 Previous chronic exposure to GHB alters preference for oral self-administration of GHB. (a) Preference 
or aversion for GHB is expressed as difference in drinking volume (ml) per mouse over 4 d for solutions with 
different GHB concentrations. Δ volume (ml) is the difference between the consumption of a GHB-containing 
sucrose solution and that of a solution of sucrose alone. Positive consumptions represent preference for GHB, 
whereas negative volumes reflect GHB aversion. Mice maximally preferred GHB at 0.01 % and developed an 
aversion to a 1 % solution (n = 4 mice in same cage for each condition). (b) Difference in drinking volume (ml) of 
orally self-administered GHB (0.01 %) after chronic injections of GHB (n = 21 mice in 7 cages) versus saline-
injected controls (n = 18 mice in 6 cages), measured at the baseline and over the 4 d of test. (c) Total 
consumption per mouse during the self-administration test for chronic saline and GHB-injected mice. 
 
- 59 - 
 
4. DISCUSSION 
 
In this study, we have shown that the low coupling efficiency between GABAB 
receptors and somato-dendritic GIRK channels is a unique feature of DA neurons. A specific 
GIRK subunit assembly seems to be responsible for that and explains the bidirectional effect 
observed in DA neurons with acute GHB treatment. In addition, the GABABR-GIRK channel 
coupling is notably modulated by chronic exposure of GHB inducing behavioral 
repercussions. In the present discussion part, we will expose all others phenomena that could 
also participate to the weak GABABR-GIRK channel coupling in the DA neurons of the VTA. 
Others VTA neurons characteristics, as GIRK currents amplitude and desensitization state, 
will be discuss here. 
 
4.1. GABABR composition in VTA neurons 
 
The production of GIRK currents in VTA neurons involves several cellular events, 
including binding of agonist, activation of GPCRs, turnover of G proteins and binding of Gβγ 
to GIRK channels. The EC50 could in principle be determined by any of these steps. However, 
the expression of a particular type of GABAB receptor or G protein in DA neurons seems 
unlikely. The GABAB receptor is an obligatory heterodimer, formed by the co-assembly of 
the GABABR1 and GABABR2 subunits (Kaupmann, Malitschek et al. 1998). Consequently, 
animals deficient in the GABABR1 subunit lack any behavioral and electrophysiological 
responses to baclofen as well as 
35
S-GTPγS binding. Receptor heterogeneity can therefore be 
associated only with splice variants of the R1 subunit (Kaupmann, Malitschek et al. 1998). 
However, heterologous expression studies have shown that GABAB receptors couple to PTX-
sensitive G proteins and have similar agonist affinities (notably for GABA, baclofen and 
GHB) and similar coupling efficiency to a number of effectors including GIRK channels 
(Pfaff, Malitschek et al. 1999). Different GABAB receptor subtypes are, therefore, unlikely to 
explain the low coupling efficiency in DA neurons. As a confirmation, we found that the 
MOR also showed a lower coupling efficiency in DA neurons than in GABA neurons. 
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Nevertheless, a different GABABR composition in VTA could still be responsible for 
others specific cellular properties. We previously saw that GABABR subtypes are differently 
expressed along the synapses in several areas of the brain and responsible for different 
cellular processes (see INTRODUCTION, § 1.3.3.2.). Pre versus postsynaptic discrimination 
of GABABR1a/2 and 1b/2, respectively, was notably observed in hippocampus and 
cerebellum. In VTA, we predicted the same situation since the function exerted by GABABRs 
on pre and postsynaptic compartments was similar as in hippocampus. However, it is still 
possible that in VTA two GABABR populations coexist at the postsynaptic side. This possible 
specific expression could explain the distinct cellular profiles between GABA and DA 
neurons in terms of GIRK currents amplitude and/or desensitization. At this time, no evidence 
appeared to sustain or confirm this hypothesis. 
 
4.2. Specific GIRK subunits composition in VTA neurons 
 
During this project, we discovered that GIRK subunits were differently expressed in 
VTA neurons. The repercussion of this specific expression in GABA and DA neurons will be 
debated in this part. 
 
4.2.1. Impact on GIRK currents amplitude/desensitization 
 
In order to confront the profile of GIRK currents in VTA neurons after the activation 
of the GABABR agonist baclofen, we collected additional data that are presented below. In 
wild-type mice, the observable difference in GIRK currents amplitude (Fig.19a, b, see also 
Fig.13) can mainly be explained by the difference of capacitance experimentally recorded in 
these cells. DA neurons generally exhibit larger cell body, larger capacitance and larger 
currents. However, we cannot exclude that some additional phenomena (e.g. cell-type specific 
GIRK surface expression) may participate to the currents amplitude. In GIRK
–/–
 mice, due to 
possible compensatory mechanisms between GIRK subunits, it is difficult to estimate the real 
contribution of each subunit to the total GIRK currents amplitude, especially for GABA 
neurons (Fig.19a, right column and Fig.19b, bottom). 
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Figure 19 Profile of VTA neurons GIRK currents in wild-type and GIRK–/– mice. (a) Example of baclofen-elicited 
currents (100µM) in DA neurons (left) and GABA neurons (right) in wild-type, GIRK1–/–, GIRK2–/–, GIRK3–/– and 
GIRK2–/–GIRK3–/– mice (from top to bottom, respectively). GABA neurons were identified by the absence of Ih and 
a response to the µ-opioid agonist DAMGO. Scale bars 25 pA / 2 min. (b) Normalized residual current against 
initial maximal amplitude of current evoked by 10 min baclofen (100 µM) in DA neurons (top) and GABA neurons 
(bottom)( n ≥ 6 for each condition, unpublished data). 
 
Besides the weak coupling efficiency to GABABRs, wild-type DA neurons also show 
desensitizing GIRK currents (Fig. 19a, top left and Fig.13a). On the other hand, the GABA 
cells exhibit currents without any desensitization (Fig. 19a, top right and Fig.13d). Thus, we 
investigated a possible link between the low coupling efficiency found in DA cells and their 
high degree of desensitization. We looked at the desensitization state after GIRK subunits 
deletion. Desensitization was still present in DA neurons of GIRK1
–/–
 and GIRK3
–/– 
mice with 
a degree similar as in wild-type but not in DA cells of GIRK2
–/–
 and GIRK2
–/–
GIRK3
–/–
 mice 
(Fig. 19a, left column and Fig.19b, top). These later observations are not surprising regarding 
the total abolishment of GIRK currents found in these cells after the deletion of GIRK2 or 
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GIRK2/3 (see RESULTS, Fig. 13c). The remaining currents showed all the characteristics of 
the Ba
2+
-resistant component normally associated to the GIRK component after GABABR 
activation. This current is known to do not desensitize (Cruz, Ivanova et al. 2004) and its 
amplitude recorded here fits with the one found previously (Fig. 13b). In addition, the 
deletion of GIRK subunits did not change the non-desensitizing profile of GABA cells. Taken 
together, these results suggest that the GIRK subunits neither determine nor influence the 
state of desensitization of the neurons of the VTA, excluding a correlation between coupling 
and desensitization. 
Finally, we tried to understand a bit more why a specific desensitization is associated 
to GIRK currents in VTA DA neurons. Currently, origin of desensitization is still unclear and 
several mechanisms are thought to mediate GIRK currents desensitization after a maintained 
GABABR activation. We examined in DA neurons a possible internalization of the GABABR, 
a mechanism already described for GPCRs (Zhang, Ferguson et al. 1998). Such phenomenon 
implicates specific receptor phosphorylation by G-protein receptor kinases (GRKs) and the 
subsequent internalization of the receptor by a scavenger protein called β-arrestin. 
Unfortunately, we did not observe any significant change in the desensitization degree of DA 
neurons in β-arrestin–/– mice where receptor internalization processes are absent (48.9 ± 2.8 % 
versus 45.6 ± 4.7 %, P > 0.05; data not shown, unpublished data). Desensitization of 
GABABR-mediated GIRK currents in DA neurons of the VTA remains an open question. 
 
4.2.2. Impact on coupling efficiency to GABABR 
 
Might the GIRK channels alone explain the low coupling efficiency found in DA 
neurons? Our high-resolution immunoelectron microscopic studies unequivocally show that 
GIRK1 is selectively expressed in TH-negative neurons whereas all neurons in the VTA 
express GIRK2 and GIRK3. Given that GIRK2 can form homomeric channels (Slesinger, 
Patil et al. 1996; Schoots, Wilson et al. 1999) or co-assemble with GIRK3 (Jelacic, Kennedy 
et al. 2000), functional channels in DA neurons could either be GIRK2 homomers or 
GIRK2/3 heteromers. Our characterization of GIRK currents in GIRK knockout mice leads us 
to conclude that GIRK2/3 heteromeric channels are present in these neurons, and might even 
constitute the majority of endogenous channels. GIRK2/3 heteromeric channels have also 
been investigated in heterologous systems. When various subunit combinations were 
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transfected in HEK293 cells, only GIRK2/3 led to a significant increase in EC50 for baclofen 
(Cruz, Ivanova et al. 2004). Moreover GIRK2/3 heteromeric channels showed a significantly 
lower affinity for Gβγ (Jelacic, Kennedy et al. 2000) than other subunit compositions. 
Together, these data indicate that the low GABAB receptor-GIRK coupling efficiency in DA 
neurons is caused by the low affinity of Gβγ for GIRK2/3 channels. This would explain why 
interventions leading to the redistribution of GIRK subunits (for example, compensatory 
mechanisms in the GIRK3
–/–
 mice or overexpression of GIRK1) led to a stronger coupling 
efficiency. It is not surprising that under these circumstances the EC50 was still higher than in 
GABA neurons, as these experiments might not fully mimic endogenous subunit expression. 
Furthermore, the EC50 measurement reflects the activity of the complex population of 
channels formed by endogenous and ectopically expressed GIRK subunits. 
In addition to GIRK channel subtypes, regulation at the receptor level, for example by 
phosphorylation, might also participate in setting the efficacy of activating GIRK channels. 
Previous experiments (done in our lab by Dr. Hans Cruz) were performed in order to block a 
possible GABABR phosphorylation. Several kinases inhibitors were tested but none of them 
showed any effect on GIRK currents amplitude and desensitization in DA neurons (data not 
shown, unpublished data). On the other hand, it has been shown that receptor phoshorylation 
by PKA facilitates the GABABR-effector coupling in neuronal preparations (Couve, Thomas 
et al. 2002). So, it could be interesting to perform experiments looking at the GABABR-GIRK 
coupling efficiency in VTA neurons after interfering with the receptor phosphorylation. 
 
4.3. GABABR-GIRK channel coupling modulation by RGS2 
 
As the GABABR-GIRK channel coupling efficiency is determined by the Gβγ 
sensitivity of particular GIRK subunit compositions, then interfering with G protein turnover 
might modulate the coupling efficiency. In a complementary study carried out in our lab by 
Marta Lomazzi, we focused on the family of RGS proteins because several of these proteins 
show highly regulated expression, which provides adaptive capabilities to many GPCRs, 
including those targeted by addictive drugs (Traynor and Neubig 2005). Although the 
function of RGS proteins that is best described is the acceleration of activation and 
deactivation kinetics (Chuang, Yu et al. 1998), they also affect receptor-effector coupling 
efficiency (Doupnik, Jaen et al. 2004). High levels of RGS proteins can increase the 
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activation and inactivation rates of GIRK channels and lower their coupling efficiencies with 
GPCRs. The innovative experiments performed in our lab highlighted the fact that RGS2 was 
expressed in DA but not in GABA neurons, implicating RGS2 in the modulation of the 
coupling efficiency in DA neurons of the VTA (Labouebe, Lomazzi et al. 2007). This role 
was confirmed by genetically silencing RGS2, which led to a higher GABAB-GIRK coupling 
efficiency. Interestingly, the increase in coupling efficiency in RGS2
–/–
 was found only when 
DA neurons also expressed GIRK3. These findings indicate that RGS2 might act selectively 
on heteromeric channels that contain GIRK3. Consistent with this, FRET measurements 
indicated that RGS2 associates with GIRK3 but not with GIRK2. Selective interactions of 
GIRK subunits with specific members of the RGS family have also been reported in other 
systems (Jaen and Doupnik 2006; Riven, Iwanir et al. 2006). Thus, the expression of specific 
GIRK subunits might determine the coupling efficiency both by altering Gβγ sensitivity and 
by recruiting selected RGS proteins to the channel. 
In the context of drugs of abuse, transcriptional regulation of RGS proteins has 
received some attention as a potential molecular mechanism underlying adaptive changes in 
addiction (Zachariou, Georgescu et al. 2003). Here, we described for the first time a change in 
the GABABR-GIRK channel coupling efficiency in VTA DA neurons after chronic GHB and 
morphine administration. The complementary study carried out by my colleague also 
indicates that the shift of the EC50 toward lower values after chronic in vivo exposure was 
caused by a reduction of RGS2 mRNA. Altogether, these results confirmed the special status 
of VTA DA neurons: a specific GIRK subunit assembly is associated to particular coupling 
modulator, together responsible for distinct cellular processes. 
 
4.4. Low coupling efficiency consequences in DA neurons 
 
A direct pharmacological consequence of chronic exposure to GHB or morphine in 
wild-type mice might be that the concentration window required for DA neurons disinhibition 
by GABAB receptor agonists becomes narrower, eventually occluding the normal increase in 
DA release. This might have implications for therapeutic approaches that aim to inhibit the 
VTA in order to attenuate craving. Baclofen is being tested in randomized clinical studies to 
treat drug addicts (Cousins, Roberts et al. 2002). Although typical doses are sufficient to 
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suppress physiological DA firing (and explain why baclofen is normally not abused) 
relatively high doses are required to block the output of the VTA in the presence of an 
addictive drug. Our findings indicate that with stronger GABABR-GIRK channel coupling, 
GHB at recreationally relevant doses might inhibit rather than excite DA neurons, thus 
abrogating the rewarding properties of the drug and thereby representing a special form of 
tolerance. Consistent with this model, chronic exposure to GHB shifted the rewarding 
properties of GHB, so that animals now self-administered less GHB than control. On the other 
hand, baclofen might be more efficient at inhibiting DA neurons in which RGS2 has been 
downregulated, enhancing its anti-craving properties. Together, the selective expression of 
GIRK channel subtypes along with varying levels of RGS2 proteins determine the coupling 
efficiency to GABAB receptors in DA neurons, providing new insight into how DA neurons 
in the VTA could be more efficiently targeted for treating drug addictions. 
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CONCLUSIONS 
 
This thesis focused on the effects of -hydroxybutyrate on the mesolimbic dopamine 
system and more particularly on the ventral tegmental area that is responsible for the 
mediation of the rewarding effects of this addictive drug. We deployed innovative 
experimental procedures to demonstrate for the first time that: 
- A weaker GABABR-GIRK channel coupling efficiency is found in DA neurons 
from mice; 
- At ultra structural level, a specific GIRK subunit composition is observed in DA 
neurons where GIRK1 is absent; 
- GIRK2/3 heteromers are responsible for this low GABABR-GIRK channel 
coupling independently to the type of GPCR implicated; 
- As a consequence, GHB exerts a bidirectional effect on the DA neurons cellular 
activity; 
- Chronic addictive drugs exposure, as GHB or morphine, increases the GABABR-
GIRK channel coupling; 
- Such coupling modulation has a direct impact on drugs of abuse consumption 
observable at the behavioral level. 
 
Taken together, these findings reveal that the metabotropic GABABR signaling we 
triggered pharmacologically, displays distinct properties between VTA neurons. Indeed, its 
strength is robustly reduced in DA neurons due to the weak coupling between the GABABR 
and the GIRK2/3 channels existing in these cells. In physiological conditions, the 
neurotransmitter GABA is responsible for inhibitory transmission in the brain via specific 
ionotropic (GABAARs) and metabotropic receptors (GABABRs). Thus, due to the low 
GABABR-GIRK channel coupling observed in DA neurons of the VTA, we expect that 
GABA transmission in these neurons will be less effective than the one in GABA neurons. 
We could verify this point directly by looking at the endogenous GABABR-evoked GABA 
transmission in VTA neurons. In the context of addiction, the modulation of the coupling 
between the GPCR and its effectors, the GIRK channels, could represent new solutions in 
order to block the rewarding properties mediation of addictive drugs as GHB. In a narrow 
future, development of molecular agents capable to increase Gβγ-GIRK2/3 sensitivity or to 
decrease RGS2 levels in DA neurons should be considered. 
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